Podcasts about lsd

Bobby Weir & John Perry Barlow's classic “The Music Never Stopped” came into being when the music was briefly in danger of stopping, the song transforming from live jam to final form as the Dead struggled to solve the financial difficulties that came with a retirement from the road.Guests: David Lemieux, Ron Rakow, Steven Schuster, Steve Silberman, Sean Howe, Shaugn O'Donnell, Chadwick Jenkins, Christopher Coffman, Graeme Boone, Eric Lindquist, Benny LanderSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if everything you've been told about anxiety only scratches the surface? We're taught to quiet our thoughts, reframe our worries, and “think positive.” But what if the real root of anxiety isn't in your head at all, it's in your body? In this transformative episode of the HEAL with Kelly Podcast, I sit down with Dr. Russell Kennedy - physician, neuroscientist, and best-selling author of Anxiety Rx, who has made it his life's mission to uncover what truly heals anxiety. Drawing from his own decades-long struggle with crippling worry, psychedelic journeys, and breakthroughs in somatic healing, Dr. Kennedy reveals how anxiety is actually an alarm state stored in the body, often rooted in unresolved childhood trauma. Together, we explore why coping strategies and pharmaceuticals often fall short, and how practices like “sensation without explanation,” breathwork, and inner child connection open the door to real healing. Dr. Kennedy also shares why suppressed anger can turn children into adults locked in victimhood, how worry tricks the brain into false certainty, and why reclaiming a spiritual connection with yourself may be the missing piece in resolving anxiety. This episode is practical, eye-opening, and deeply human. If you've ever wrestled with anxiety or love someone who has, Dr. Kennedy's wisdom will help you understand it in a whole new way, and guide you back to a place of calm, safety, and inner trust. Key Moments You'll Love ✨:

Ed Prideaux discusses the the phenomenon of "Psychedelics Flashbacks" and how they relate to Hallucinogen Perception Persisting Disorder, also known as as HPPD. ... This is a clip from 'Hallucinogen Perception Persisting Disorder (HPPD) | Ed Prideaux ~ ATTMind Podcast 152 FULL INTERVIEW Listen on iTunes Listen on Spotify Watch on YouTube Read the show notes   SUPPORT THE PODCAST

Send us a textWhat happens when talk therapy isn't enough? When the pain runs so deep that even the best therapist can't reach it? Curt Kearney joins today to share his personal story of turning to psychedelics as a last resort and how that decision changed the entire trajectory of his life.This is a deeply grounded conversation about trauma, treatment-resistant depression, and the inner parts we exile to survive. Curt breaks down how Internal Family Systems (IFS) and psychedelic-assisted therapy can work together to bring those parts back into relationship, sometimes for the first time in decades. This is not a conversation about quick fixes. It's about safety, trust, and the power of showing up for the parts of ourselves we were taught to bury.This Episode Covers:Curt's first experience with LSD at 17 and how it altered his mental health journey.The difference between exiles and protectors in IFS.How psychedelics can amplify self-compassion and internal clarity.The importance of preparation and consent in psychedelic work.A powerful case study of MDMA-assisted therapy for PTSD.Why “bad trips” often come from neglected parts not feeling safe.The role of integration and ongoing relationship with inner parts.What happens when the monster inside turns out to be you.Connect with Curt:LinkedIn - https://www.linkedin.com/in/curt-kearney-39824643/Website - https://www.curtkearney.com/Until next time, here's to deeper connections and personal growth.Mad love!The podcast is now on YouTube! If you prefer to watch, head over to https://www.youtube.com/playlist?list=PLw3CabcJueib20U_L3WeaR-lNG_B3zYqu__________________________________________Don't forget to subscribe to the Badass Confidence Coach podcast on your favorite podcast platform!CONNECT WITH ANNA:Instagram https://www.instagram.com/askannamarcolin/TikTok https://www.tiktok.com/tag/askannamarcolinEmail hello@annamarcolin.comWebsite https://www.annamarcolin.com

“We don't view a person with chronic pain as someone who has a chronic illness and the effect of that is we can't follow patients continuously over prolonged periods of time,” says Dr. Jacob Hascalovici, a neurologist and pain specialist based in New York City.  In co-founding Bliss Health, Dr. Jacob, as he is known, has set out to create a continuous care model for chronic pain treatment that matches the approach taken for patients with diabetes or high blood pressure. The Bliss Health formula includes an initial meeting with a physician that produces a care plan; remote therapeutic monitoring on an ongoing basis; and a monthly meeting with a nurse to review data and determine next steps, including additional appointments with physicians as needed.  All of this occurs via a digital platform which provides a welcome option for patients with mobility issues and can fill gaps in access to specialists, especially in rural areas. Dr. Jacob is also hoping to make chronic pain patents feel respected, which is not always the case in their encounters with the healthcare system. “Because pain is not something that can be seen or measured, oftentimes patients feel marginalized, dismissed and disempowered by providers.” Join Raise the Line host Lindsey Smith for a valuable conversation that also touches on policy changes that could strengthen telemedicine, and has details on the first non-opioid based pain medication to receive FDA approval in over 20 years.Mentioned in this episode:Bliss Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In recent months, public health advocates in the United States have raised concerns about proposed changes to vaccine policy, cuts to food assistance programs, rollbacks of environmental protections and reductions in public health staffing. Chief among them has been Dr. Georges Benjamin who, as executive director of the American Public Health Association (APHA) since 2002, has led national efforts to create a healthier America. Raise the Line host Lindsey Smith recently sat down with Dr. Benjamin to understand more about the current state of public health and explore the path forward, and learned that a top priority for APHA is battling the misinformation that Dr. Benjamin believes is fueling support for many of these changes. “The challenge we have right now is that as a society, we've gone into our little corners and live in our own ecosystems. More people are getting their information from a single source and they're not validating that information to make sure that it's true.” Tune into this thoughtful and timely conversation to hear Dr. Benjamin's advice for curbing the spread of misinformation, how APHA is trying to help people understand the value of public health initiatives, and what the U.S. can learn from other countries about improving public health. Mentioned in this episode:American Public Health Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

SPONSORS: 1) MIZZEN & MAIN: Right now, Mizzen & Main is offering our listeners 20% off your first purchase at https://mizzenandmain.com, promo code JULIAN20 PATREON https://www.patreon.com/JulianDorey (***TIMESTAMPS in description below) ~ Sarma Melngailis is an American chef, cookbook author, businesswoman and ex-convict. She was the owner and co-founder of the formerly highly-regarded Pure Food and Wine restaurant in New York City. FOLLOW JULIAN DOREY INSTAGRAM (Podcast): https://www.instagram.com/juliandoreypodcast/ INSTAGRAM (Personal): https://www.instagram.com/julianddorey/ X: https://twitter.com/julianddorey SARMA's LINKS - Substack: https://substack.com/@sarmamelngailis?r=16p9u&utm_medium=ios - IG: https://www.instagram.com/sarmamelngailis/ - X: https://x.com/sarma - WEBSITE: https://www.sarmaraw.com/writing/2022/4/5/bad-vegan-is-not-a-documentary JULIAN YT CHANNELS - SUBSCRIBE to Julian Dorey Clips YT: https://www.youtube.com/@juliandoreyclips - SUBSCRIBE to Julian Dorey Daily YT: https://www.youtube.com/@JulianDoreyDaily - SUBSCRIBE to Best of JDP: https://www.youtube.com/@bestofJDP ****TIMESTAMPS**** 00:00 - Intro 01:22 - Netflix ignoring Psychological Abuse, Nexivm, Stolen Youth, Parents' Divorce 10:50 - Sarma's Autism Diagnosis, Aspergers, Sensory Disorder, Telepathy Tapes 21:53 - Thought Reading, Autism as Superpower, LSD at 13, Blue Hair Girl 32:01 - Unsupervised Childhood, Young Girls Spectrum, Older Friends, Skaters 42:36 - Book Cut Story, Virginity taken at 14, Childhood Trauma, Psychopaths, Rescue Animals 53:06 - Manipulation, Memory Holes, Vulnerability, Kids, Love & Attachment, Sick Attachment 01:02:46 - Pure Love, Younger Guys, Jealousy, Defining Love 01:13:29 - Jealousy, Cona Atists Reformed?, Sociopaths, Victim Blaming, Awareness 01:23:50 - Hyper Awareness, Second Opinions, Judging People 01:34:26 - Love Reading, Penn, Wharton, Wall St, Culinary School, Frat House 01:45:00 - Wall St, Culinary School, Brief Marriage, Wife Role 01:56:01 - Settling vs Love, Divorce, Chaos, Fighting, Extremes 02:07:27 - Conflict Avoidance, Anxiety, Friendships, Love Languages, Fear Asking Help 02:20:33 - Burden, Affirmations, Culinary School, Food, Veganism, First Scheme CREDITS: - Host, Editor & Producer: Julian Dorey - COO, Producer & Editor: Alessi Allaman - https://www.youtube.com/@UCyLKzv5fKxGmVQg3cMJJzyQ - In-Studio Producer: Joey Deef - https://www.instagram.com/joeydeef/ Julian Dorey Podcast Episode 342 - Sarma Melngailis Learn more about your ad choices. Visit podcastchoices.com/adchoices

Discograffiti is the deep-dive podcast for music obsessives.  In this episode, Beach Boys author Chuck Granata reviews and discusses Pet Sounds' “I Know There's An Answer” (originally written as "Hang On To Your Ego") and “Here Today,” with commentary and stories. Discograffiti's Pet Sounds Deep-Dive Series stands as a unique combination of factual obsession and personal connection, and there's nothing else like it.  Here are just a few of the many things that Chuck discusses with Discograffiti in this podcast: The extremely illuminating original title of “Hang On To Your Ego”; Some background info on little-known “Ego” co-writer Terry Sachen; The impact of LSD on Brian's consciousness during that time; The difficulty that Tony Asher had with writing lyrics to “Here Today”; The fraught relationship that Brian Wilson had with “Here Today”; The Four Seasons song that may have been a “Here Today” influence; And how both Chuck and I connect with “I Know There's An Answer” / “Hang On To Your Ego” and “Here Today” in a laid-bare, explicitly personal way. Listen: linktr.ee/discograffiti I support a wife and a six-year-old son with Discograffiti as my sole source of income.  The Director's Cut of this episode is ad-free and features a plethora of additional essential material. Support Discograffiti by opting for this clearly superior version. Either subscribe to Discograffiti's Patreon at the Lieutenant or Major Tier, or just grab the episode as a one-off at the same link. The Director's Cut: Patreon.com/Discograffiti Chuck Granata's book Wouldn't It Be Nice: Brian Wilson And The Making Of The Beach Boys' Pet Sounds is the ultimate dissection of Brian Wilson's 1966 masterpiece.  Order it on Amazon or at your favorite brick n mortar bookstore.    CONNECT Join our Soldiers of Sound Facebook Group: https://www.facebook.com/groups/1839109176272153 Patreon: www.Patreon.com/Discograffiti Podfollow: ⁠⁠https://podfollow.com/1592182331⁠⁠ YouTube Channel: https://www.youtube.com/channel/UClyaQCdvDelj5EiKj6IRLhw Instagram: https://www.instagram.com/discograffitipod/ Facebook: https://www.facebook.com/Discograffiti/ Twitter: https://twitter.com/Discograffiti Order the Digital version of the METAL MACHINE MUZAK 2xLP (feat. Lou Barlow, Cory Hanson, Mark Robinson, & W. Cullen Hart): www.patreon.com/discograffiti/shop/197404 Order the $11 Digital version of the MMM 2xLP on Bandcamp: https://discograffiti.bandcamp.com/album/metal-machine-muzak Order the METAL MACHINE MUZAK Double Vinyl + Digital package: www.patreon.com/discograffiti/shop/169954 Merch Shop: https://discograffitipod.myspreadshop.com/all Venmo Dave A Tip: @David-Gebroe Web site: http://discograffiti.com/   CONTACT DAVE Email: dave@discograffiti.com Facebook: https://www.facebook.com/hooligandave Instagram:  https://www.instagram.com/davidgebroe/ Twitter: https://twitter.com/DaveGebroe There is no other Patreon in existence where you get more for your money. 4 shows a week is what it takes these days to successfully blot out our unacceptable reality…so do yourself a favor and give it a shot for at least one month to see what I'm talking about.   If you're already a member, please comment below about your experience.   www.Patreon.com/discograffiti

In this episode Rotem Petranker, PhD joins to discuss the current state of research on microdosing psilocybin. Dr. Petranker is the co-founder of the Psychedelic Studies Research Program at the University of Toronto and the Canadian Centre for Psychedelic Science. He recently ran the world's largest randomized controlled trial on the effectiveness of microdosing psilocybin on Major Depressive Disorder. In this conversation, Dr. Petranker shares insights from running the world's largest randomized controlled trial on psilocybin microdosing for major depressive disorder. He explains the origins of microdosing research, from early anecdotes and surveys to his team's carefully designed clinical study comparing psilocybin to placebo across different environments. While participants in both groups reported significant improvements, the findings point to the powerful role of expectancy and placebo effects, alongside nuanced signals of cognitive shifts on measures like dysfunctional attitudes. Dr. Petranker emphasizes the importance of rigorous methodology, open science, and transparency in psychedelic research, while also acknowledging the stories of participants whose lives were positively impacted by study participation itself.   In this episode, you'll hear: What early microdosing research suggested, and its limitations in anecdotal and survey-based designs Why psilocybin was chosen over LSD for the study design  What motivates people to try microdosing a psychedelic Key results from Dr. Petranker's study, including reports of both positive and adverse events How placebo effects—and simply being part of a trial—can powerfully shape outcomes Reflections on how psychedelics may work by increasing connectedness   Quotes: “There's no real rigorous definition [of microdosing]. People say, ‘oh, I'm just going to microdose some mushrooms,' and then they often take a random amount. I think what people mean is ‘I'm going to take an amount that will not knock me out, won't cause serious hallucinations,' but they still use an amount that they often feel. Now, this is in contrast to what people in the [academic] literature define it as, which is more like a sub-perceptual dose, a sub-hallucinogenic dose.” [2:17] “If you microdose and go to work, just to sit under the flickering lights for eight hours in your cubicle versus, say, if you're going to microdose and then go on a walk, or do art, or do as you wish because it's the weekend, you're going to have very different impacts on your anxiety.” [15:26] “[In our study] there were three other self-report measures of depression. There is only a significant difference on one of them, where people who were microdosing were doing better. And that was on the dysfunctional attitude scale, which measures more cognitive assumptions about life.” [26:2] “people who microdose—regardless of why they microdose—they more or less all said that they got to what they wanted through an increased sense of meaning.” [35:05]   Links: Psychedelic Studies Research Program at the University of Toronto Canadian Centre for Psychedelic Science website Canadian Centre for Psychedelic Science on X Canadian Centre for Psychedelic Science on Instagram Previous episode: Microdosing and the Placebo Effect with Balazs Szigeti, PhD Previous episode: James Fadiman answers your Microdosing Questions! Psychedelic Medicine Association Porangui  

“Probably the most exciting thing I've seen in gene therapy over the last ten years is we now have a lot of tools for selective delivery, which will hopefully make treatments more safe and a lot more successful,” says Dr. Jessica Duis, a geneticist and pediatrician focused on the management of individuals with complex, rare disorders. Dr. Duis, who has worked on several gene therapies that are now approved or progressing through the accelerated approval pathway, is currently VP of Clinical Development at GondolaBio, a clinical-stage biopharmaceutical company focused on developing therapeutics for genetic diseases. As you'll learn in this Year of the Zebra episode with host Lindsey Smith, Dr. Duis is encouraged by other recent advances in genetic technology as well, and thinks momentum will grow as breakthrough treatments emerge. “I think we're hopefully going to continue to see companies that are working in rare disease be more successful and really drive how regulators think about making decisions in terms of bringing treatments to patients. I think we're at the tip of the iceberg in terms of the future of truly transformational therapies.”  This wide ranging conversation also explores Dr. Duis' team approach to patient care, her work on clinical endpoints, the importance of patient communities, and her book series, Rare Siblings Stories.Mentioned in this episode:GondolaBioRareDiseaseDocElsevier Healthcare Hub on Rare DiseasesRare Sibling Stories If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Weltweit, auch in der Schweiz, erleben psychedelische Substanzen ein Revival. LSD, MDMA und Psilocybin – manchmal auch in Microdosen – sind aus der Partyszene nicht mehr wegzudenken. Aber auch im medizinischen Kontext werden sie immer häufiger gegen Depressionen oder Suchtkrankheiten eingesetzt. Die Schweiz mischt ganz vorne mit. Mit Ausnahmebewilligungen dürfen Psychiater und Psychologen LSD, MDMA, Ayahuasca oder Psilocybin einsetzen. Das Universitätsspital Genf hat eine eigene Abteilung dafür geschaffen und bildet Medizinstudierende entsprechend aus. Halluzinogene werden auch weiter erforscht, um Medikamente zur Behandlung von Depressionen, Ängsten, posttraumatischen Belastungsstörungen oder Suchterkrankungen herzustellen. Auf dem globalen Pharma-Markt winkt damit das grosse Geschäft, denn immer mehr Menschen haben psychische Probleme. Braucht es heute Tabletten oder einfach Ekstase, um das durchgetaktetes Leben auszuhalten? Ist die so erzielte Verbundenheit mit der Natur effektiv ein Weg zur psychischen Heilung und zu einer besseren Welt? Oder ist dieser neue Hype nur eine weitere Kommerzialisierung der Natur, bei der einige wenige Firmen grosse Gewinne machen? Der Film von Michèle Sauvain zeigt, wo die Schweiz steht.

Weltweit, auch in der Schweiz, erleben psychedelische Substanzen ein Revival. LSD, MDMA und Psilocybin – manchmal auch in Microdosen – sind aus der Partyszene nicht mehr wegzudenken. Aber auch im medizinischen Kontext werden sie immer häufiger gegen Depressionen oder Suchtkrankheiten eingesetzt. Die Schweiz mischt ganz vorne mit. Mit Ausnahmebewilligungen dürfen Psychiater und Psychologen LSD, MDMA, Ayahuasca oder Psilocybin einsetzen. Das Universitätsspital Genf hat eine eigene Abteilung dafür geschaffen und bildet Medizinstudierende entsprechend aus. Halluzinogene werden auch weiter erforscht, um Medikamente zur Behandlung von Depressionen, Ängsten, posttraumatischen Belastungsstörungen oder Suchterkrankungen herzustellen. Auf dem globalen Pharma-Markt winkt damit das grosse Geschäft, denn immer mehr Menschen haben psychische Probleme. Braucht es heute Tabletten oder einfach Ekstase, um das durchgetaktetes Leben auszuhalten? Ist die so erzielte Verbundenheit mit der Natur effektiv ein Weg zur psychischen Heilung und zu einer besseren Welt? Oder ist dieser neue Hype nur eine weitere Kommerzialisierung der Natur, bei der einige wenige Firmen grosse Gewinne machen? Der Film von Michèle Sauvain zeigt, wo die Schweiz steht.

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_US

Episode summary Joe and Mary dive into how platform censorship and shifting algorithms have reshaped psychedelic media, why DoubleBlind moved to a “newsletter-first” model, and what that's revealed about true audience engagement. They reflect on the post-2024 MDMA decision headwinds, state-level policy moves (wins and losses), and how funding, politics, and culture continue to reconfigure the field. They also explore alternatives to alcohol, chronic pain research, reciprocity around iboga/ibogaine, and lessons from PS25 (MAPS' Psychedelic Science 2025). Highlights & themes From platforms to inboxes: Social and search suppression (IG/FB/Google) throttled harm-reduction journalism; DoubleBlind's pivot to email dramatically improved reach and engagement. Post-MDMA decision reality: Investment cooled; Mary frames it as painful but necessary growth—an ecosystem “airing out” rather than a catastrophic pop. Policy pulse: Mixed year—some state measures stalled (e.g., MA), others advanced (e.g., NM; ongoing Colorado process). Rescheduling cannabis may add complexity more than clarity. Censorship paradox: Suppressing education makes use less safe; independent outlets need community support to keep harm-reduction info visible. Chronic pain & long COVID: Emerging overlaps and training efforts (e.g., Psychedelics & Pain communities) point beyond a psychiatry-only frame. Alcohol alternatives: Low-dose or occasional psychedelic use can shift habits for some; Mary stresses individual context and support beyond any single substance. Reciprocity & iboga: Rising interest (including from right-leaning funders) must include Indigenous consultation and fair benefit-sharing; pace of capitalism vs. community care is an active tension. PS25 field notes: Smaller, more manageable vibe than 2023; fewer “gold-rush” expectations; in-person dialogue beats online flame wars. Notable mentions DoubleBlind: Newsletter-first publishing; nurturing new writers and reported stories. Psychedelics & Pain Association / Clusterbusters: Community-driven models informing care and research (cluster headache protocols history). Books & media: Body Autonomy (Synergetic Press anthology); Joanna Kempner's work on cluster headaches - Psychedelic Outlaws; Lucy Walker's forthcoming iboga film. Compounds to watch: LSD (under-studied relative to MDMA), 2C-B, 5-MeO-DMT (synthetic focus), and broader Shulgin-inspired families.   Mary Carreon: [00:00:00] Okay, I'm gonna send it to my dad because he wants to know. Here Joe Moore: we go. Yeah, send it over. So, hi everybody. We're live Joe here with Mary Anne, how you doing today? Mary Carreon: I'm great Joe. How are you? Joe Moore: Lovely. I actually never asked you how to pronounce your last name does say it right? Mary Carreon: Yes, you did. You said it perfectly Joe Moore: lovely. Joe Moore: Um, great. So it's been a bit, um, we are streaming on LinkedIn, YouTube, Twitch X and Kick, I guess. Yeah. Kick meta. Meta doesn't let me play anymore. Um, Mary Carreon: you're in forever. Timeout. I got it. I got it. Yeah. Joe Moore: Yeah. I think they found a post the other day from 2017. They didn't like, I'm like, oh cool. Like neat, you Mary Carreon: know, you know. Mary Carreon: Yeah. That happened to me recently, actually. Uh, I had a post taken down from 2018 about, uh, mushroom gummies and yeah, it was taken down and I have strikes on my account now. So Joe Moore: Do you get the thing where they ask you if you're okay? Mary Carreon: Yes, with, but like with my searches though, [00:01:00] like if I search something or, or someone's account that has, uh, like mushroom or psychedelic or LSD or something in it, they'll be like, mm-hmm are you okay? Mary Carreon: And then it recommends getting help. So Joe Moore: it's like, to be fair, I don't know if I'm okay, but Yeah, you're like, probably not. I don't really want your help. Meta. Yeah. Mary Carreon: You're like, I actually do need help, but not from you. Thanks. Yeah, Joe Moore: yeah, yeah. Mary Carreon: So not from the techno fascists. Joe Moore: Oh, good lord. Yeah. Uh, we'll go there. Joe Moore: I'm sure. Mary Carreon: I know. I just like really dove right there. Sorry. Yeah. All right, so let's, Joe Moore: um, before we go, let's give people like a bit of, you know, high kicks on, on who is Mary, where you working these days and what are you doing? Mary Carreon: Yeah, thank you. My name is Mary Carryon and I am forever and first and foremost a journalist. Mary Carreon: I have been covering, I say the plant legalization spaces for the past decade. It's, it's been nine and a half years. Uh, on January 3rd it will be [00:02:00] 10 years. And I got my start covering cannabis, uh, at OC Weekly. And from there went to High Times, and from there went to Mary Jane, worked for Snoop Dogg. And then, uh, I am now. Mary Carreon: Double blind. And I have become recently, as of this year, the editor in chief of Double Blind, and that's where I have been currently sinking my teeth into everything. So currently, you know, at this moment I'm an editor and I am basically also a curator. So, and, and somebody who is a, uh, I guess an observer of this space more than anything these days. Mary Carreon: Um, I'm not really reporting in the same way that I was. Um, but still I am helping many journalists tell stories and, uh, I feel kind of like a story midwife in many ways. Just like helping people produce stories and get the, get the quotes, get the angles that need to be discussed, get the sentences structures right, and, um, uh, helping [00:03:00] sometimes in a visionary kind of, uh, mindset. Mary Carreon: So yeah, that's what I'm doing these days. Joe Moore: Oh, there it is. Oh, there you are. Love that. And um, you know, it's important to have, um, editors who kind of really get it from a lot of different angles. I love that we have a lot of alignment on this kind of, and the drug war thing and kind of let's, uh, hopefully start developing systems that are for people. Joe Moore: Yeah, absolutely. If you wanna just say that. Yeah, absolutely. Mary Carreon: Yeah, absolutely. Joe Moore: So, um, yeah, I almost 10 years in January. That's great. We um, it's so crazy that it's been that long. I think we just turned nine and a half, so we're maybe just a few, a few months shorter than your I love it. Plant medicine reporting career. Joe Moore: That's great. I love it. Um, yeah, so I think. I think one of the first times we chatted, [00:04:00] um, I think you were doing a piece about two cb Do you, do you have any recollection of doing a piece on two cb? Mary Carreon: I do, yes. Yes. Wait, I also remember hitting you up during an Instagram live and I was like, are you guys taking any writers? Mary Carreon: And you guys were like writers, I mean, maybe depending on the writer. Joe Moore: And I was like, I was like, I dunno how that works. Mary Carreon: Like me. Yeah. Joe Moore: Yeah. It was fun. It was fun to work with people like yourself and like get pieces out there. And eventually we had an awesome editor for a bit and that was, that was really cool to be able to like support young startup writers who have a lot of opinions and a lot of things to point out. Joe Moore: There's so much happening. Um, there was so much fraud in like wave one. Of kind of the psychedelic investment hype. There's still some, but it's lesser. Um, and it's really a fascinating space still. Like changing lives, changing not just lives, right? Like our [00:05:00] perspective towards nearly everything, right? Joe Moore: Yeah. Mary Carreon: Yes, absolutely. Absolutely. I mean, it's interesting because the space has matured. It's evolved. It's different than it was even, what a, I mean, definitely nine years ago, but even five years ago, even four years ago, even last year, things are different. The landscape is different than it was a year ago. Mary Carreon: And I, it's, it's interesting to see the politics of things. It's interesting to see who has money these days given like how hard it is just to kind of survive in this space. And it's interesting just to. Bear witness to all of this going down because it really is a once in a lifetime thing. Nothing is gonna look the same as it does now, as it, uh, then it will like in a, in a year from now or anything. Mary Carreon: So it's really, yeah. It's interesting to take account of all of this Joe Moore: That's so real. Uh, maybe a little [00:06:00] too real, like it's serious because like with everything that's going on from, um, you know, governance, governments, ai Yes. Drug policy shifts. Drug tech shifts, yes. There's so much interesting movement. Um, yes. Joe Moore: You, you know, you, you kind of called it out and I think it's really actually worth discussing here since we're both here on the air together, like this idea that the psychedelic market, not idea, the lived experience of the psychedelic market having shifted substantially. And I, I, I think there's a lot of causes. Joe Moore: But I've never had the opportunity to really chat with you about this kind of like interesting downturn in money flowing into the space. Mm-hmm. Have you thought about it? Like what might the causes be? I'm sure you have. Mary Carreon: Yeah. Yeah, I have. Yeah. I've thought about it. I mean, it's hard. Well, I don't know. I am really not trying to point fingers and that's not what I'm [00:07:00] trying to do here. Mary Carreon: But I mean, I think a lot of people were really hopeful that the FDA decision last June, not last June, the previous June, a year ago, 2024, June was going to open the floodgates in terms of funding, in terms of, um. In terms of mostly funding, but also just greater opportunities for the space and, uh, greater legitimacy granted to the psychedelic medicine space. Mary Carreon: Mm. And for those who might not know what I'm talking about, I'm talking about the, uh, FDA decision to reject, uh, MDMA assisted therapy and, um, that whole, that whole thing that happened, I'm sure if it, you didn't even have to really understand what was going on in order to get wind of that wild situation. Mary Carreon: Um, so, so maybe, yeah. You probably know what I'm talking about, but I, I do think that that had a great impact on this space. Do I think it was detrimental to this space? [00:08:00] I don't think so. We are in a growth spurt, you know, like we are growing and growing pains happen when you are evolving and changing and learning and figuring out the way forward. Mary Carreon: So I think it was kind of a natural process for all of this and. If things had gone forward like while, yeah, there probably would be more money, there would be greater opportunity in this space for people wanting to get in and get jobs and make a living and have a life for themselves in this, in this world. Mary Carreon: I don't know if it was, I don't know if it would necessarily be for the betterment of the space in general for the long term. I think that we do have to go through challenges in order for the best case scenarios to play out in the future, even though that's difficult to say now because so many of us are struggling. Mary Carreon: So, but I, but I have hope and, and that statement is coming from a place of hope for the future of this space and this culture. Joe Moore: Yeah. It's, um, I'm with [00:09:00] you. Like we have to see boom bust cycles. We have to see growth and contraction just like natural ecosystems do. Mary Carreon: Absolutely, absolutely. It has to be that way. Mary Carreon: And if it's not that way, then ifs, if. It's, it like what forms in place of that is a big bubble or like a, a hot air balloon that's inevitably going to pop, which, like, we are kind of experiencing that. But I think that the, I think that the, um, the, the air letting out of the balloon right now is a much softer experience than it would be if everything was just like a green light all the way forward, if that makes sense. Mary Carreon: So, Joe Moore: right. And there's, there's so many factors. Like I'm, I'm thinking about, uh, metas censorship like we were talking about before. Yes. Other big tech censorship, right? Mm-hmm. SEO shifts. Mary Carreon: Oh. Um, yes, absolutely. Also, uh, there were some pretty major initiatives on the state level that did not pass also this past year that really would've also kind of [00:10:00] helped the landscape a little bit. Mary Carreon: Um. In terms of creating jobs, in terms of creating opportunities for funding, in terms of having more, uh, like the perception of safer money flow into the space and that, you know, those, those things didn't happen. For instance, the measure for in Massachusetts that didn't go through and just, you know, other things that didn't happen. Mary Carreon: However, there have been really good things too, in terms of, uh, legalization or various forms of legalization, and that's in New Mexico, so we can't, you know, forget that there, and we also can't forget just the movement happening in Colorado. So there are really great things happening and the, the movement is still moving forward. Mary Carreon: Everything is still going. It's just a little more difficult than maybe it could have been Joe Moore: right. Yeah. Amen. Amen. Yes. But also, we Mary Carreon: can't forget this censorship thing. The censorship thing is a horse shit. Sorry. I'm not sure if I'm allowed to cuss, but it is, [00:11:00] but it is Joe Moore: calling it out and it's important to say this stuff. Joe Moore: And you know, folks, if you want to support independent media, please consider supporting Doubleblind and psychedelics today. From a media perspective, absolutely. We wanna wanna put as much out as we can. Yes. The more supporters we have, the more we can help all of you understand what's happening and yes. Joe Moore: Getting you to stay safer. Mary Carreon: Yeah, absolutely. And that's the whole difficulty with the censorship is that psychedelics today, and Doubleblind for instance, but also Lucid News, also other, uh, other influencers, other creators in the space, they like. What all of us are doing is putting out information that is ultimately creating a safer user experience. Mary Carreon: And so with the censorship, we are not able to do so anymore, which creates actually a lot of danger. So. Yeah, it's, it's difficult. The censorship is difficult, and if you are somebody who posts about psychedelics, I know that you know this and I am preaching to the choir. Joe Moore: Yeah. So can you talk a [00:12:00] little bit about you all at Double Blind made a major shift in the last number of months towards, uh, kind of not necessarily putting everything out there and, and kind of like, um, actually I don't even know the language you use. Joe Moore: What's the, what's the language you use for the kind of model shift you took on? Mary Carreon: Yeah, I mean, it's great. It's been a wild shift. It's been a wild shift. Um, what we are currently doing is we went to a newsletter first model, which instead of just posting onto a website for everyone to see, and then, um, you know, hopefully getting SEO hits and also posting on their, then posting those stories onto Instagram and Facebook and Twitter, and hoping to get traffic through social media. Mary Carreon: Uh, we decided that that was no longer working for us because it wasn't, um, because the censorship is so bad on, on social media, like on Instagram, for instance, and Facebook and Twitter, well, less on Twitter, [00:13:00] but still, nonetheless on social media, the censorship is so bad. And also the censorship exists on Google. Mary Carreon: When you Google search how to take mushrooms, double blinds is not even on. You know, our guide is not on the first page. It's like, you know, way the heck, way the heck down there. Maybe page 2, 3, 4, 5. I don't know. But, um, the issue, the issue with that, or, or the reason why rather that it's that way is because Google is prioritizing, um, like rehabilitation centers for this information. Mary Carreon: And also they are prioritizing, uh, medical information. So, like WebMD for instance. And all of these organizations that Google is now prioritizing are u are, are, are, are organizations that see psychedelic use through the lens of addiction or through drug drug abuse. So [00:14:00] again, you know, I don't know, take it for how you want to, I'm not gonna say, I'm not gonna tell anybody like what is the right way to use their substances or whatever. Mary Carreon: However, it's really important to have the proper harm reduction resources and tools available. Uh, just readily available, not five pages down on a Google search. So anyways, all of that said double blind was our traffic was way down. And it was looking very bleak for a while. Just we were getting kicked off of Instagram. Mary Carreon: We weren't getting any traffic from social media onto our website, onto our stories. It was a, it was a vicious kind of cycle downward, and it wasn't really working. And there was a moment there where Doubleblind almost shut down as a result of these numbers because there's a, like you, a media company cannot sustain itself on really low page views as a result. Mary Carreon: So what we [00:15:00] decided to do was go to a newsletter first model, which relies on our email list. And basically we are sending out newsletters three days a week of new original content, mostly, uh, sometimes on Wednesdays we repost an SEO story or something like that. Um, to just to engage our audience and to work with our audience that way, and to like to actually engage our audience. Mary Carreon: I cannot emphasize that enough because on Instagram and on Facebook, we were only reaching like, I don't know, not that many people, like not that many people at all. And all of that really became obvious as soon as we started sending out to our email list. And as soon as we did that, it was wild. How many, how many views to the website and also how many just open like our open rate and our click through rate were showing how our audience was reacting to our content. Mary Carreon: In other words. [00:16:00] Social media was not a good, in, like, was not a good indicator of how our content was being received at all because people kind of weren't even receiving it. So going to the newsletter first model proved to be very beneficial for us and our numbers. And also just reaching our freaking audience, which we were barely doing, I guess, on social media, which is, which is wild, you know, for, for a, an account that has a lot of followers, I forget at this exact moment, but we have a ton, double blind, has a ton of followers on, on Instagram. Mary Carreon: We were, we, we get like 500 likes or, you know, maybe like. I don't know. If you're not looking at likes and you're looking at views, like sometimes we get like 16 K views, which, you know, seems good, but also compared to the amount of followers who follow us, it's like not really that great. And we're never reaching new, like a new audience. Mary Carreon: We're always reaching the same audience too, [00:17:00] which is interesting because even with our news, with our, with our email list, we are still reaching new people, which is, which says just how much more fluid that space is. Mm-hmm. And it's because it's, because censorship does not at least yet exist in our inboxes. Mary Carreon: And so therefore email is kind of like the underground, if you will, for this kind of content and this type of material journalism, et cetera. So, so yeah. So it, it, it has been a massive shift. It is required a lot of changes over at double blind. Everything has been very intense and crazy, but it has been absolutely worth it, and it's really exciting that we're still here. Mary Carreon: I'm so grateful that Double-Blind is still around, that we are still able to tell stories and that we are still able to work with writers and nurture writers and nurture the storytelling in this space because it needs to evolve just the same way that the industry and the [00:18:00] culture and everything else is evolving. Joe Moore: Yeah, I think, I think you're spot on like the, when I watch our Instagram account, like, um, I haven't seen the number change from 107 K for two years. Mary Carreon: Absolutely. Same. And, um, same. Joe Moore: Yeah. And you know, I think, I think there's certain kinds of content that could do fine. I think, uh, psychedelic attorney, Robert Rush put up a comment, um, in response to Jack Coline's account getting taken down, um, that had some good analysis, um. Joe Moore: Of the situation. Go ahead. You had No, Mary Carreon: no, I'm just like, you know, I can't, when, when journalists are getting kicked off of these, of these platforms for their stories, for their reported stories, that's like, that is a massive red flag. And that's all I have to say. I mean, we could go into more, more details on that, but that is a [00:19:00] huge red flag. Joe Moore: Mm-hmm. Yeah. Um, for sure. The, I, yeah. And like I'm sure he'll get it back. I'm sure that's not for good, but I think he did. Okay, great. Mary Carreon: I think he did. Yeah. Yeah, I think he did. Joe Moore: Yeah. So thank you. Shout out to Jack. Yeah, thanks Jack. Um, and I think, you know, there's, there's no one with that kind of energy out there. Joe Moore: Um, and I'm excited to see what happens over time with him. Yeah. How he'll unfold. Absolutely unfold. Oh yeah. It's like, um. Crushing the beat. Mary Carreon: Oh yeah, absolutely. Especially the political, the political beat. Like, there's no, there's few people who are really tackling that specific sector, which is like mm-hmm. Mary Carreon: So exciting for a journalist. Joe Moore: Yeah. Um, so model shifting, like we all have to like, adapt in new ways. Kyle and I are still trying to figure out what we're gonna do. Like maybe it is newsletter first. Like I, I realized that I hadn't been writing for [00:20:00] years, which is problematic, um, in that like, I have a lot of things to say. Mary Carreon: Totally. Joe Moore: And nobody got to hear it. Um, so I started a substack, which I had complicated feelings about honestly. 'cause it's just another. Rich person's platform that I'm, you know, helping them get Andreessen money or whatever. And, you know, so I'm gonna play lightly there, but I will post here and there. Um, I'm just trying to figure it all out, you know, like I've put up a couple articles like this GLP one and Mushrooms article. Mary Carreon: I saw that. I saw that. Really? And honestly, that's a really, like, it's so weird, but I don't, like, it's such a weird little thing that's happening in the space. I wonder, yeah, I wonder, I wonder how that is going to evolve. It's um, you know, a lot of people, I, I briefly kind of wrote about, um, psychedelics and the GLP, is that what it is? Mary Carreon: GLP one. Joe Moore: GLP one. Say Ozempic. Yeah, just, yeah, Ozempic. Yeah, exactly. Mary Carreon: Yeah, exactly. I wrote about [00:21:00] that briefly last year and there were a bunch of people like obviously horrified, which it is kind of horrifying, but also there's a bunch of people who believe that it is extremely cutting edge, which it also is. Mary Carreon: So it's really interesting, really fascinating. Joe Moore: Yeah. Um, I remember Bernie Sanders saying like, if this drug gets as much traction as it needs to, it will bankrupt Medicaid. I guess that's not really a problem anymore. Um, but, but, uh, but so like naming it real quick, like it changed the way we had to digest things, therefore, like mushrooms get digested differently and, um, some people don't respond in the expected ways. Joe Moore: And then there was some follow up, oh, we, in the regulated model, we just do lemon tech. And then I was like, is that legal in the regulated model? And I, I don't know the answer still. Mm-hmm. Like there was a couple things, you know, if users know to do it, you know, I don't, I don't totally understand the regulated model's so strange in Oregon, Colorado, that like, we really need a couple lawyers opinions. Joe Moore: Right. I think Mary Carreon: yes, of course Joe Moore: the lawyers just gave it a [00:22:00] thumbs up. They didn't even comment on the post, which is, laughs: thanks guys. Um, Joe Moore: but you know, laughs: yeah. You're like, thank you. Joe Moore: Thanks and diversity of opinions. So yeah, there's that. And like GLP ones are so interesting in that they're, one friend reached out and said she's using it in a microdose format for chronic neuroinflammation, which I had never heard of before. Joe Moore: Whoa. And um, I think, you know, articles like that, my intent was to just say, Hey, researchers yet another thing to look at. Like, there's no end to what we need to be looking at. Abso Mary Carreon: Oh, absolutely, absolutely. You know, reporting on this space actually taught me that there's so much just in general that isn't being researched, whether that's in this space, but also beyond and how, um, yeah, just how behind, actually, maybe not, maybe behind isn't the right word, but it kind of feels from my novice and from my novice place in the, in the world and [00:23:00] understanding research, it's. Mary Carreon: Hard for me to see it as anything, but being behind in the research that we all really need, that's really going to benefit humanity. But also, you know, I get that it's because of funding and politics and whatever, whatever, you know, we can go on for days on all of that. Joe Moore: What's the real reason? What's the real reason? Joe Moore: Well, drug war. Mary Carreon: Yeah. Well, yeah, definitely the drug war. Nixon. Yeah. Yes, yes, definitely the drug war. Yeah. I mean, and just the fact that even all of the drug research that happens is, again, through the lens of addiction and drug abuse, so Joe Moore: mm-hmm. Hard to right. Yeah. Um, like ni a is obviously really ridiculous and, and the way they approach this stuff, and Carl Hart illustrates that well, and, Mary Carreon: oh man, yes, he does. Joe Moore: Like, I think Fadiman's lab in Palo Alto got shut down, like 67, 66 or 67, and like that's, you know, that was one of the later ones, Mary Carreon: right? And, Joe Moore: and like, Mary Carreon: and here we are. Joe Moore: The amount of suffering that could have been alleviated if we [00:24:00] had not done this is. Incalculable. Um, yes. Yes. Yeah. Mary Carreon: I mean the, yeah, it's hard to say exactly how specifically it would be different, but it's difficult to also not think that the fentanyl crisis and the opioid addiction rate and situation that is currently like plaguing the, the world, but particularly the United States, it's hard to think that it wouldn't be, like, it wouldn't be a different scenario altogether. Joe Moore: Right, right. Absolutely. Um, and it's, um, it's interesting to speculate about, right? Like Yeah. Yes. Where would we be? And Mary Carreon: I know, I know, I know, I know it is speculation. Absolutely. But it's like hard, as I said, it's hard not to think that things would be different. Joe Moore: Right. Right. Um, I like, there's two kind of quotes, like, um, not, this one's not really a quote. Joe Moore: Like, we haven't really had a [00:25:00] blockbuster psychiatric med since Prozac, and I think that was in the eighties or early nineties, which is terrifying. And then, um, I think this guy's name is James Hillman. He is kinda like a Jungian, um, educator and I think the title of one of his books is, we're a hundred Years Into Psychotherapy and the World is Still a Mess. Joe Moore: And I think like those two things are like, okay, so two different very white people approaches didn't go very far. Yes. Um, yes and laughs: mm-hmm. Joe Moore: Thankfully, I think a lot of people are seeing that. Mm-hmm. Um, finally and kind of putting energy into different ways. Um, Mary Carreon: yeah. Absolutely. I think, yeah, I mean, we need to be exploring the other options at this point because what is currently happening isn't working on many fronts, but including in terms of mental health especially. Mary Carreon: So mm-hmm. We gotta get going. Right? We [00:26:00] gotta get moving. Geez. Joe Moore: Have you all, have you all seen much of the information around chronic pain treatments? Like I'm, I'm a founding board member with the Psychedelics and Pain Association, which has a really fun project. Oh, that's interesting. Mary Carreon: Um, I've seen some of the studies around that and it's endlessly fascinating for obvious, for obvious reasons. Mary Carreon: I, um, we have a writer who's been working for a long time on a story, uh, about the chronic pain that has since. Become an issue for this, for her, for the writer. Mm-hmm. Um, since she had COVID. Mm-hmm. Since, since she is just like, COVID was the onset basically of this chronic pain. And, um, there she attended a psychedelics in pain, chronic pain conference and, uh, that has pretty much like, changed her world. Mary Carreon: Um, well, in terms of just the information that's out there, not necessarily that she's painless, but it's just, you know, offering a, a brand new, a brand new road, a brand new path that is giving her, [00:27:00] um, relief on days when the pain is, uh, substantial. laughs: Yeah. Mary Carreon: So that's interesting. And a lot of people are experiencing that as well. Joe Moore: Mm-hmm. So there's, there's a really cool set of overlap between the COVID researchers, long COVID researchers and the chronic pain people. 'cause there is Yes. This new science of pain that's yes. Our group, PPA put out like a really robust kind of training, um, for clinicians and researchers and even patients to get more educated. Joe Moore: And we're, we're getting, um, kind of boostered by cluster busters and we're kind of leveraging a lot of what they've done. Mary Carreon: Wait, what is a cluster buster? Joe Moore: Oh gosh. Um, so they're a 5 0 1 C3. Okay. Started with Bob Wald. Okay. Bob Wald is a cluster headache survivor. Oh, oh, oh, Mary Carreon: okay. Got it. Got it. Yes. So they're Joe Moore: the charity that, um, has been really championing, um, cluster headache research because they found a protocol [00:28:00] with mushrooms. Joe Moore: Yes, yes, yes. To eliminate. Mm-hmm. Yeah. Um, this really great, I Mary Carreon: love that. Joe Moore: This really great book was written by a Rutgers, um, I think medical sociologist or anthropologist psychedelic. Love laughs: that. Joe Moore: Joanna Kempner. Cool. Um, and it kind of talks about the whole, um, cluster busters saga, and it was, it was pretty cool. Joe Moore: Nice. So they've been at it for about as long as maps. Um, oh wow. Maybe a little earlier. Maybe a little later. Mary Carreon: I love that. Cool. I mean, yeah, that's really great. That's really great. Joe Moore: So we're copying their playbook in a lot of ways and Cool. We about to be our own 5 0 1 C3 and, um, nice. And that should be really fun. Joe Moore: And, uh, the next conference is coming up at the end of next month if people wanna check that out. Psychedelic. Nice. Mary Carreon: Nice, nice, nice. Cool. Joe Moore: Yeah, so that, like, how I leaned into that was not only did I get a lot of help from chronic pain with psychedelics and going to Phish shows and whatever, um, you know, I, and overuse for sure helped me somehow. Joe Moore: [00:29:00] Um, God bless. Yeah. But I, I like it because it breaks us out of the psychiatry only frame for psychedelics. Mm. And starts to make space for other categories. Mm-hmm. Is one of the bigger reasons I like it. Mary Carreon: Mm-hmm. Mm-hmm. Yes. Yes. Which, like, we need to be, we need to, we, no one else is gonna do it for us. We like the people in the space who are finding new uses for these substances need to be creating those, those pathways and those new niches for people to then begin studying, et cetera, and exploring and yeah. Mary Carreon: Making, making a proper avenue for, Joe Moore: right, right. And, you know, um, I don't know that this is a Maha thing, so No, I'm going there, I guess, but like, how do we kind of face squarely America and the world's drinking problems? Not [00:30:00] knowing what we know now about alcohol, you know what I mean? And then like, what are the alternatives? Joe Moore: You know, some, some writers out there on substack are very firm that everybody needs to not do any substance. And like all psychedelics are super bad and drugs are evil, you know, famous sub stackers that I won't name. But you know, like what is the alternative? Like, I, like we have to have something beyond alcohol. Joe Moore: And I think you've found some cannabis helpful for that. Mary Carreon: Yeah, I, you know, it's, it's interesting because it's, there are, there's definitely an argument to be made for the power of these substances in helping, I don't wanna, I don't wanna say curb, but definitely reduce the symptoms of, uh, wanting to use or to drink or to consume a specific substance. Mary Carreon: There's obviously there is an argument to be made. There are, there is ano another camp of people who are kind [00:31:00] of in the, in the, in the, in the realm of using a drug to get off of a drug isn't how you do it. However, and, and I do, it depends on the individual. It depends on the individual and the, and how that person is engaging with their own addiction. Mary Carreon: I think for whether or not the substances work, like whether psychedelics work to help somebody kind of get off of alcohol or get off of cocaine or stop using opioids or, you know, et cetera. Mm-hmm. However, I think like, when the situation is so dire, we need to be trying everything. And if that means, like, if, like, you know, if you look at the studies for like smoking cessation or alcohol use, mushrooms do help, psilocybin does help with that. Mary Carreon: Mm-hmm. But, you know, there's, there's a lot of, there's a lot of things that also need to happen. There's a lot of things that also need to happen in order for those, uh, that relief to maintain and to stick and to, uh, really guide [00:32:00] somebody off of those substances. Mm-hmm. It's not just the substance itself. Joe Moore: Right. So I'm, I'm explicitly talking like recreational alternatives, right. Like how do I Yeah. On per minute, like, am Anitas becoming helpful? Yeah, yeah. Are helpful and Yeah. Yeah. I think like even, um, normal. What we might call like normal American alcohol use. Like Yeah. That's still like, quite carcinogenic and like, um, absolutely. Joe Moore: We're kind of trying to spend less as a country on cancer treatments, which I hope is true. Then how do we, how do we develop things that are, you know, not just abstinence only programs, which we know for sure aren't great. Mary Carreon: Yeah. They don't work. Yeah. I don't, it's, it's difficult. Mm-hmm. It's difficult to say. Mary Carreon: I mean mm-hmm. I don't know. Obviously I, I, well, maybe it's not obvious at all for people who don't know me, but, you know, I exist in a, I exist in, in a world where recreational use is like, it's like hard to define what recreational use is because if we are using this, if we are using mushrooms or LSD even, or MDMA, [00:33:00] you know, there are so many, there's a lot of the therapy that can happen through the use of these substances, even if we're not doing it, you know, with a blindfold on or whatever and yeah, I think like. Mary Carreon: There is a decent swap that can happen if you, if you are somebody who doesn't wanna be, you know, having like three beers a night, or if you are somebody who's like, you know, maybe not trying to have like a bottle of wine at a night or something like that, you know, because like Americans drink a lot and a lot of the way that we drink is, um, you know, like we don't see it as alcoholism. Mary Carreon: Even though it could be, it could be that's like a difficult Joe Moore: potentially subclinical, but right there. Mary Carreon: Um, yeah. Yeah. It's like, you know, it's, um, we don't see it as that because everybody, a lot of people, not everybody, but a lot of people drink like that, if that makes sense. If you know mm-hmm. If you, if you get what I'm, if you get what I'm saying. Mary Carreon: So, you know, I do think that there's a lot of benefit that, I don't [00:34:00] know, having, like a, having a mushroom, having a mushroom experience can really help. Or sometimes even like low dose, low doses of mushrooms can also really help with, like, with the. Desire to reach for a drink. Yeah, totally. And, and AMS as well. Mary Carreon: I know that that's also helping people a lot too. And again, outside of the clinical framework. Joe Moore: Yeah. I'm, a lot of people project on me that I'm just like constantly doing everything all the time and I'm, I'm the most sober I've been since high school. You know, like it's bonkers that like Yeah. Um, and you know, probably the healthiest event since high school too. Joe Moore: Yeah. But it's fa it's fascinating that like, you know, psychedelics kind of helped get here and even if it was like For sure something that didn't look like therapy. Yeah, Mary Carreon: yeah, yeah, yeah. Absolutely. Absolutely. Yeah. I, I think, I think most of us here in this space are getting projected on as to like, you know, being like what Normies would consider druggies or something, or that we are just like, you know, high all the time. Mary Carreon: Um, [00:35:00] I know that that is definitely something that I face regularly, like out in the world. Um, but, you know, I would also, I would also argue that. Uh, like mushrooms have completely altered my approach to health, my approach to mental health, and not even having to consume that, you know, that substance in order or that, you know, that fun fungi, in order for me to like tap into taking care of my mental health or approaching better, uh, food options, et cetera. Mary Carreon: It's kind of like what these, it's like how the mushrooms continue to help you even after you have taken them. Like the messages still keep coming through if you work with them in that capacity. Right. And yeah, and also same with, same with LSD too. LSD has also kind my experiences with that have also guided me towards a healthier path as well. Mary Carreon: I, I understand that maybe for some people it's not that way, but, um, for me that substance is a medicine as well, [00:36:00] or it can be. Joe Moore: Yeah. Um, so. What are, what are some things popping up these days about like US drug policy that's like getting exciting for you? Like, are you feeling feeling like a looming optimism about a, a major shift? Joe Moore: Are you kind of like cautiously optimistic with some of the weird kind of mandatory minimum stuff that's coming up or? Mary Carreon: Yeah. Yeah. I mean, I know that there was a huge, a, a pretty huge shift over at the DEA and I wish I remembered, I wish I remembered his name. The new guy who's now, I believe the head of the DEA, I don't know enough information about it to really feel a way. Mary Carreon: However, I don't think that he's necessarily going to be serving us as a community here, uh, in the psychedelic space. I, you know, I just don't think that that's something that we can ever depend on with the DEA. Uh, I also don't think that [00:37:00] the DEA is necessarily going to be. All that helpful to cannabis, like the cannabis space either. Mary Carreon: Um, I know that, that Trump keeps kind of discussing or, or dangling a carrot around the rescheduling of cannabis. Um, for, he's been, he's been, but he's doing it a lot more now. He's been talking about it more recently. Uh, he says like, in the next like couple weeks that he's going to have some kind of decision around that, allegedly. Mary Carreon: But we will see also, I'm not sure that it's going to necessarily help anybody if we reschedule two. Uh, what from schedule one to schedule th two, three, schedule three. Joe Moore: Either way it's like not that useful. Right. Exactly. Mary Carreon: Yeah. Yeah, exactly. It's, um, just going to probably cause a lot more red tape and a lot of confusion for the state rec markets. Mary Carreon: So it's like something that we, it's like only ridden with unintentional, unintentional consequences. Unintended consequences. Mm-hmm. Because no one knows how it's really going to [00:38:00] impact anything, um, if, if at all. But I don't know. It's hard, it's hard to imagine that there won't be any, uh, like more complex regulatory issues for business owners and also probably consumers as well. Joe Moore: Hmm. Yeah. This guy's name's Terry Cole. Mary Carreon: Oh, the new DEA guy. Joe Moore: Yeah. Um, I don't know much about him. Terry. Yeah. Terry, I would love to chat. Mary Carreon: Yeah. Terry, let's talk. I'm sure your people Joe Moore: are watching. Yeah. So like, just let him know. We wanna chat. Yeah. We'll come to DC and chat it out. Um, yeah. It's, um, but yeah, I, Carl Hart's solution to me makes like almost most of the sense in the world to just end the scheduling system Absolutely. Joe Moore: And start building some sort of infrastructure to keep people safe. That's clearly not what we have today. Mary Carreon: No. But building an infrastructure around the health and wellness and uh, safety of [00:39:00] people is the exact opposite system that we have currently right now. Because also the scheduling system has a lot to do with the incarceration in the United States and the criminal just, or the criminal system. Mary Carreon: So, so yeah, like we can't disentangle the two really. Joe Moore: It just started, um, I feel negligent on this. Uh, synergetic press put out a book like a year or two ago called Body Autonomy. Mm-hmm. Um, did that one come across your desk at all? Mm-hmm. No. I wish basically contributed. Oh, nice. A number of people. So it's both like, um. Joe Moore: Drug policy commentary and then like sex work commentary. Oh, nice. And it was like high level, like love that really, really incredible love that detailed science based conversations, which is not what we have around this. Like, that doesn't make me feel good. So you should go to jail kind of stuff. Or like, I'm gonna humiliate you for real though. Joe Moore: Ticket. Yeah, Mary Carreon: yeah, yeah, yeah, yeah. Oh God. Uh, when you think about it like that, it just really also shows [00:40:00] just the uh, um, the level at which religion has also kind of fundamentally infused itself into the scheduling system, but also our laws, you know, like what you just said, this like, shame-based, I'm going to embarrass you and make you into a criminal when you know actually you are a law for the most part, a law abiding citizen, with the exception of this one thing that you're doing for. Mary Carreon: A, your survival and or your, like, your feeling good, wanting to feel good addressing pain. Um, there's a large, uh, like noise coming out of the front yard of my house right now. Hold on. Just a, it doesn't sound too bad. It doesn't sound too bad. Okay. Okay, good. Not at all. Not at all. Okay. Yeah, I had Joe Moore: people working on my roof all day and somehow it worked out. Joe Moore: Oh, good. Um, yeah. Um, yeah, it's, it's fascinating and I, I've been coming around like, I, I identify as politically confused, [00:41:00] um, and I feel like it's the most honest way I can be. Um, Mary Carreon: I am also politically confused these days, impossible to align with any, uh, party or group currently in existence at this exact juncture in American history. Joe Moore: I can't find any that I want to throw my dice in with. Nah. This idea of like fucking way being. Like what is the most humane way to do government as a way it's been put to me recently. And that's interesting. So it comes down to like coercion, are we caring for people, things like that. And um, I don't think we're doing it in a super humane way right now. Mary Carreon: Um, we, yeah, I am pretty sure that even if there was, I mean, I think that even if we looked at the data, the data would support that we are not doing it in a humane way. Joe Moore: So Mary Carreon: unfortunately, and Joe Moore: you know, this whole tech thing, like the tech oligarch thing, you kind of dropped at the beginning and I think it's worth bringing that back because we're, we're on all [00:42:00] these tech platforms. Joe Moore: Like that's kind of like how we're transmitting it to people who are participating in these other platforms and like, you know, it's not all meta. I did turn on my personal Facebook, so everybody's watching it there. I hope. Um, see if that count gets, Mary Carreon: um, Joe Moore: but you know, this idea that a certain number of private corporations kind of control. Joe Moore: A huge portion of rhetoric. Um, and you know, I think we probably got Whiffs of this when Bezos bought Washington Post and then Yes. You know, Musk with X and like yes. You know, is this kind of a bunch of people who don't necessarily care about this topic and the way we do, and they're like in larger topics too about humane government and like, you know, moving things in good directions. Joe Moore: Um, I don't know, thoughts on that rift there as it relates to anything you, wherever you wanna go. Yeah. Mary Carreon: Yeah. I mean, I don't think that they are looking at, I don't think that they are looking [00:43:00] at it the way that we are. I don't think that they can see it from their vantage point. Um, I think that like, in the, in a similar way that so many CEOs who run businesses have no fucking clue about what's actually happening in their businesses and the actual workers and, and employees of their businesses can tell them in more detail. Mary Carreon: Far more detail about what's actually happening on the, on the floor of their own business. Uh, I think that it is something like that. However, that's not to say that, you know, these, these CEOs who employ people who build the A algorithm are obviously guided to create the limitations on us as people who speak about drugs, et cetera, and are creating a algorithm that ultimately is looking at things in a very blanket way in terms of, uh, like we're probably seen on the same level as like drug dealers, if that makes sense. Mary Carreon: Which is obviously a much, you know, there's, [00:44:00] it's a very different thing. Um, so, you know, there's like these CEOs are giving directions to their employees to ultimately create systems that harm. Information flow and inform and, and like the information health of, of platforms and of just people in general. Mary Carreon: So it's hard to say because there's nuance there, obviously, but I would bet you that someone like Elon Musk doesn't really have a full grasp as to the, the nuances and details of what's even happening within, on the ground floor of his businesses. Because that's like, not how CEOs in America run, run, and operate. Mary Carreon: They're stupid companies. So, so yeah. And I feel like that, like, that's across the board, like that's across the board. That's how I, that's probably how Zuck is operating with Meta and Facebook, et cetera. And yeah, just likewise and across, across the whole, [00:45:00] across the whole spectrum. Joe Moore: Mm-hmm. Yeah. And I think, um, a thing. Joe Moore: Then as the people like, we need to keep looking at how can we keep each other informed. And that's kind of circling back to drug journalism like we do and like, um, other, other sorts of journalism that doesn't really get the press it deserves. Right. And I've been getting far more content that I find more valuable off of tragically back on Zucks platform like IG is getting me so much interesting content from around the world that no major outlet's covering. Mary Carreon: That's so interesting. Like what? Like what would you say? Joe Moore: Oh, um, uh, certain, um, violent situations overseas. Oh, oh, got it. Yeah, yeah, yeah. And, um, you know, that America's paying for, so like, you know, I just don't love that I don't have a good, you know, journalistic source I can [00:46:00] point to, to say, hey, like right. Joe Moore: These writers with names, with addresses, like, and offices here. Yes. You know, they did the work and they're held, you know, they're ethical journalists, so yes. You can trust them. Right. You know what I mean? Yes, Mary Carreon: yes. Yeah, yeah, yeah. I mean, all of this makes everything so much harder for determining, like, the censorship specifically makes it so much harder for the people to determine like, what's real, what's not. Mary Carreon: Because, because of exactly what you just said. Mm-hmm. Like, you know, we are, we are basically what that means, like what is required of the people and people who are consuming information is becoming a smart consumer and being able to determine what's real, what's not. How can we trust this individual? Mary Carreon: How can we not, which isn't analysis process that all of us need to be sharpening every single day, especially with the advent of AI and, uh, how quickly this, this type of content is coming at all of us. Like, especially if you're on TikTok, which many of us are, you know, like information comes flying at you 3000 miles an hour, and it's sometimes [00:47:00] really difficult to determine what's real, what's not, because AI is. Mary Carreon: AI is not where it's going to be, and it still is in its nascent phase. However, it's still pretty fucking good and it's still very confusing on there. So, so again, like the media literacy of the people needs to be sharpened every single day. We cannot be on there, we cannot be on the internet existing. Mary Carreon: That everything that we are seeing is real. Whether that's about, you know, these, um, the violence overseas, uh, happening at the hands of the United States, whether that is, uh, even drug information like, you know, et cetera, all of all of it. Or just like news about something happening at Yellowstone National Park or something that is happening in the, uh, at like. Mary Carreon: Um, like potential riots also happening at protests in downtown la, et cetera. Like all, all of it, we need to be so careful. And I think what that also, like, one way that [00:48:00] we can adjust and begin to develop our media literacy skills is talking to people maybe who are there, reaching out to people who are saying that they were there and asking them questions, and also sussing that out. Mary Carreon: You know, obviously we can't do that for all situations, but definitely some of them. Joe Moore: Yeah, absolutely. Like, Joe Moore: um, a quick pivot. Mm-hmm. Were you at PS 25? Mary Carreon: Yes, I was. What did I think? Uh, you know, I, I was running around like crazy at this one. I felt like I didn't even have a second to breathe and I feel like I didn't even have a second to really see anybody. I was like, worry. I was jumping from one stage to the next. Mary Carreon: However, I would say, uh, one of, one of the things that I have said and how I felt about it was that I felt that this, this event was smaller than it was two years ago. And I preferred that I preferred the reduction in size just because it was, uh, less over, less overwhelming [00:49:00] in an, in an already very overwhelming event. Mary Carreon: Um, but I thought that from the panels that I did see that everyone did a really great job. I thought that maps, you know, it's impressive that maps can put on an event like that. Um, I also was very cognizant that the suits were there in full effect and, uh, you know, but that's not unusual. That's how it was last time as well. Mary Carreon: And, um, I felt that there was Mary Carreon: a, uh, like the, the, the level of excitement and the level of like opportunity and pro, like the prosperous. The like, prospect of prosperity coming down the pipeline like tomorrow, you know, kind of vibe was different than last time. Mm-hmm. Which that was very present at the one, two years ago, uh, which was the last PS psychedelic science. Mary Carreon: Yeah. Um, anyways. Yeah. But it was, you know, it was really nice to see everybody. [00:50:00] I feel like in-person events is a great way for everybody in the psychedelic space to be interacting with each other instead of like keyboard warrioring against each other, you know, uh, over the computer and over the internet. Mary Carreon: I think that, um, yeah, uh, being in person is better than being fighting each other over the internet, so, yeah. Joe Moore: Mm-hmm. People seem to be a little bit more civil in person. Mary Carreon: Exactly. Exactly. Mm-hmm. And I think that that is something that we all need to be considering more often, and also inviting people from across the aisle to your events and creating peace, because in person it's a little different than it is. Mary Carreon: When you have the opportunity to, uh, yeah, like keyboard attack someone over the internet, it's like, yeah. It's just so silly. So silly. We look like fools. Like we look like absolute idiots doing that. And you know what? I cannot sit here and say that I haven't looked like an idiot. So, you know, it's like I'm not, I'm not talking from like a high horse over here, but, but you know, it's like, it's [00:51:00] better when it's in person. Mary Carreon: I feel like there's like more civil engagements that we can all have. Joe Moore: It's practice, you know? Yeah. We're learning. Yeah. We are. We should be learning, including us, and yes, of course. Um, I, I play a subtler game these days and, uh, you know, I, I, I, it's better when we all look a lot better in my opinion, because yes, we can inform policy decisions, we can be the ones helping inform really important things about how these things should get implemented and absolutely right. Joe Moore: Like, Mary Carreon: absolutely. Yeah, it does. It does. Nobody, any service, especially these medicines, especially these sacraments, especially these plants, these molecules, et cetera, if we are all sitting here fighting each other and like calling each other names and trying to dunk on one another, when like in reality, we are also all kind of pushing for the same thing more or less. Joe Moore: Mm-hmm. So a thing that [00:52:00] I, it's a, it's kind of a, I, I had a great time at PS 25. I have no, no real complaints. I just wish I had more time. Yeah, same. Um, same. Yeah. Our booth was so busy. It was so fun. Just good. And it was like, good. I, I know. It was really good. I'm trying to say it out loud. I get to talk at the conference before Rick did. laughs: Oh, oh, Joe Moore: the morning show they put us on at like seven 30 in the morning or something crazy. Oh my god. It was early. I dunno if it was seven 30. Mary Carreon: That's so early. That's so early. Joe Moore: Yeah, right. Like that's crazy. I got zero nightlife in That's okay. Um, I was not, I was there for work. Yeah, Mary Carreon: yeah. I was Joe Moore: jealous. I didn't party, but you know, whatever. Joe Moore: Yeah, yeah. Mary Carreon: I did not party this time really in the same way that I did at PS 20. Was it 2023? Joe Moore: 23, yeah. 23. I only stay up till 11 one night in 23. Nice. Mary Carreon: Okay. Um, okay. Joe Moore: So I behaved, I have a pattern of behaving. 'cause I like That's good. I'm so bent outta shape inside going into these things. I'm like, I know, I know. Joe Moore: And, and I'm like, oh, all [00:53:00] my friends are gonna be there. It's gonna be great. And then it's like, yeah. It's mostly friends and only a little bit of stress. Yeah. Um, yeah. Yeah, Mary Carreon: yeah. I had a, I had a great time. It was really good seeing everybody again. Like you, I wish that I had more time with people. Like there are people that I like didn't even see who are my friends, Joe Moore: so, which Yeah. Joe Moore: Which is sad. That's like a subtext in, in like the notes coming away from 25. Is that the, um, American Right, if we wanna call it that, is very interested in this stuff. Oh yeah. Like the Texas establishment. Oh yeah. Um, the Texas contingent, right? They're deep. They're real deep. Mm-hmm. I have, um, Mary Carreon: let's talk about that more. Mary Carreon: Yeah. So Joe Moore: it's optimistic in, in some sense that psychedelic science is getting funded more. By states. 'cause the feds aren't stepping up. Right. I love that. Right. Yeah. Like, Hey feds, look what we can do. And you can't somehow, and [00:54:00] then, um, we'll see if state rights stays around for a while longer, maybe, maybe not. Joe Moore: And then the other part is like, is there a slippery slope given the rhetoric around addiction and the rise in interest in iboga for compulsory addiction treatment with psychedelics or, or compulsory mental health treatments with psychedelics because of the recent, it's illegal to be a person without housing. Joe Moore: Um, and you're gonna get put in treatment. Mm. Like, that's now a thing. So like, I don't know, I don't think forced treatment's good at all. I, and I don't think like, um, like the data is something like 15% effective, maybe less. Right. Right. It's not a good use of money. I don't know. We're, let's, I. You can go there if you want, and riff on that, or if you wanna talk about like, Texas, um, Arizona more generally. Mary Carreon: Yeah. I mean, I will just say this, I also don't really believe that forced treatment is like good, you [00:55:00] know, data Joe Moore: says it's bad. Mary Carreon: Yeah. Yeah. I also, yeah, I mean, it's like, I don't know. Yeah, that's, it's complex. It's a complex issue. I also don't think it's good, but I also do think that we need a much better framework and foundation for like, if people do want the help, helping them get it. Mary Carreon: Much more easily and in a way that's going to be beneficial for them. Um, and I don't think that that system or that pathway currently exists as we saw in, uh, with, with, um, measure 1 0 9 and the failure of measure 1 0 9 or, or was it Measure 1 0 10, 1 10, measure one 10 in Oregon. Joe Moore: But did you see the response yesterday or two days ago? Joe Moore: No, I didn't. No, I didn't. I'll I'll send it to you later. Okay. So the university did the research, um, Portland State University did the research Yes. And said, Hey, look, there was actually 20 other things that were higher priority. Like that actually influenced this increase in overdoses, not our law. Mary Carreon: Right. Mary Carreon: Yes. It was really COVID for Okay. [00:56:00] Like for, yeah. Right. Absolutely. Also, there was not a. Like there was not a framework in place that allowed people to get off the street should they want to, or you know, like, like you just can't really have a, all drugs are legal, or small amounts of drugs are legal without also offering or creating a structure for people to get help. Mary Carreon: That, that's, you can't do one without the other. Unfortunately. That's just like a, that's faulty from the start. So that's all I'll really say about that. And I don't think that that had fully been implemented yet, even though it was something that wasn't ideal for the, um, for the, for the measure. And I believe it was measure one 10, not measure 1 0 9, to be clear. Mary Carreon: Measure one 10. Um, yes, but confirmed one 10 confirmed one 10, yes. Mm-hmm. Um, but yeah, uh, that's, you know, that's kind of what I'll say. That's what I'll, that's where I'll leave that portion. Mm-hmm. You know? Uh, but yeah, forced treatment. I don't know. [00:57:00] We can't be forcing, forcing people to do stuff like that. Mary Carreon: I don't know. It's not gonna, it's, yeah, it doesn't seem Joe Moore: very humane. Mary Carreon: Yeah. No. And it also probably isn't gonna work, so, Joe Moore: right. Like, if we're being conservative with money, like, I like tote, like to put on Republican boots once in a while and say like, what does this feel like? And then say like, okay, if we're trying to spend money smartly, like where do we actually get where we want to be? Joe Moore: And then sometimes I put on my cross and I'm like, okay, if I'm trying to be Christian, like where is the most, like, what is the most Christian behavior here in terms of like, what would the, you know, buddy Jesus want to do? And I'm just like, okay, cool. Like, that doesn't seem right. Like those things don't seem to align. Joe Moore: And when we can find like compassionate and efficient things, like isn't that the path? Um, Mary Carreon: compassionate and t. Yeah, even, I don't know, I don't know if it looks lefty these days, but Yeah, I know what you mean. Yeah, I know what you mean. I know what you mean. Yeah. [00:58:00] Yeah. Um, yeah, it's complicated. It's complicated, you know, but going back, kind of, kind of pivoting and going back to what you were talking about in regards to the subtext, some of the subtext of like, you know, where psychedelic medicine is currently getting its most funding. Mary Carreon: You know, I do believe that that was an undercurrent at psychedelic science. It was the, the iboga conversation. And there's, there's a lot, there's a lot happening with the Iboga conversation and the Iboga conversation and, um, I am really trying to be open to listening to everyone's messages that are currently involved in. Mary Carreon: That rise of that medicine right now? Um, obviously, yeah, we will see, we'll see how it goes. There's obviously a lot of people who believe that this is not the right move, uh, just because there's been no discussions with, uh, the Wii people of West Africa and, you know, because of [00:59:00] that, like we are not talking to the indigenous people about how we are using their medicine, um, or medicine that does like that comes from, that comes from Africa. Mary Carreon: Um, also with that, I know that there is a massive just devastating opioid crisis here that we need to do something about and drug crisis that we need to be helping with. And this medicine is something that can really, really, really help. Um, I find it absolutely fascinating that the right is the most interested party in moving all of this forward, like psychedelic medicine forward. Mary Carreon: And I, I currently have my popcorn and I am watching and I am eating it, and I am going to witness whatever goes down. Um, but I'm, I, I hope that, uh, things are moving in a way that is going to be beneficial for the people and also not completely leave behind the indigenous communities where this medicine comes from. Joe Moore: [01:00:00] Mm-hmm. Mary Carreon: We'll see how it goes. Yeah. We'll see how it goes. We'll see how it goes. It Joe Moore: would be lovely if we can figure it out. Um, I know, and I think, uh, Lucy Walker has a film coming out on Iboga. Mm. I got to see it at Aspen, um, symposium last summer, and it was really good. Mm. So I'm sure it'll be cut different, but it's so good and it tells that story. Joe Moore: Okay. Um, in a helpful way. I'm gonna, I, yeah. I always say I'm gonna do this. I'm like, if I have space, maybe I'll be able to email her and see if we can screen it in Colorado. But it's like a brilliant film. Yeah. Cool. This whole reciprocity conversation is interesting and challenging. And so challenging being one of the few countries that did not sign onto the Nagoya protocol. Joe Moore: Absolutely. We're not legally bound, you know, some countries are Mary Carreon: I know. Yes, yes, yes. So Joe Moore: we're, you know, how do we do that? How do we do that skillfully? We still haven't done it with, um, first Nations folks around their [01:01:00] substances. Um, I think mushrooms are a little flexible and account of them being global, um, from Africa to Ireland and beyond. Joe Moore: And, but you know, that's, we still want to give a nod to the people in Mexico for sure. Yeah, absolutely. Absolutely. Yeah. Um, yeah. Yeah, it's, I had some fun commentary there that I would love to flesh out someday. Uh, but yeah, it's not for today. Mary Carreon: Yeah, yeah, yeah. Um, there's, yeah, there's obviously, there's obviously a lot with the conversation of reciprocity here and, um, I know, I, I don't know. Mary Carreon: I, I, what I do know is that we need to be listening to the indigenous people, not just listening to them second, like secondhand or listening to them, uh, once we have moved something forward, like actually consulting with them as the process goes. And that, you know, the way that both parties move, indigenous folks and, uh, western folks move, uh, are at inherently different paces. Mary Carreon: And, [01:02:00] um, I just hope, and I wish, and I, I hope, I just hope that, uh, Western what, like the Western party, the western folks who are diving into these medicines. Slow the fuck down and listen and just are able to at least make one right move. Just one, just like you. Like it's, doesn't have to be this, it doesn't have to be that hard. Mary Carreon: Although the pace of capitalism usually propels, uh, the western folks at, at a much quicker rate than, u

This week we're discussing every album by the completely insane Cardiacs. If you aren't familiar with this band, then you're going to need to take a seat and prepare yourself. Led by the late Tim Smith and his brother Jim, Cardiacs are a prog band like no other in existence. You just have to hear them. Their final album, LSD, was just released after almost 20 years of painstaking writing, recording, and devastating health problems. This is one of our most requested bands and one that will stay with us for years to come.   Intro/Band Overview 00:00 The Seaside 20:57 Songs for Ships and Irons 36:57 A Little Man and a House and the Whole World Window 48:13 On Land and in the Sea 1:01:39 Heaven Born and Ever Bright 1:17:53 Sing to God 1:32:58 Guns 1:58:18 Tim Smith's Health Battles 2:10:36 LSD 2:18:08 Outro 2:39:59   ----------------------------------------------------------------------------------------------------------   Patreon https://www.patreon.com/everyalbumever   Merch https://pandermonkey.creator-spring.com/   Mike's EP: Pander Monkey on Bandcamp, Spotify, Apple,   Mike on Instagram @pandermonkey Alex on Bluesky @octatron3030 Tom on Instagram @tomosmansounds   History Tom's stuff: Music on Spotify, Apple Podcast on Spotify, YouTube Substack Website   ----------------------------------------------------------------------------------------------------------   Mike's Picks: Sing to God (1996) -- Best Album A Little Man and a House and the Whole World Window (1988) -- Personal Favorite On Land and in the Sea (1989) -- Worst Album, Least Favorite   Alex's Picks: LSD (2025) -- Best Album A Little Man and a House and the Whole World Window (1988) -- Personal Favorite Guns (1999) -- Worst Album, Least Favorite   Albums we discussed this episode... The Seaside (1984) Songs for Ships and Irons (1991) A Little Man and a House and the Whole World Window (1988) On Land and in the Sea (1991) Heaven Born and Ever Bright (1992) Sing to God (1996) Guns (1999) LSD (2025)

Is there an uptick of people claiming to be actual witches? When in history were witches NOT seen as evil? Is this commercialism packaged as a spiritual practice? Julie Walsh, PhD, is the Whitehead Associate Professor of Critical Thought & Associate Professor of Philosophy at Wellesley College in Massachusetts. Her primary research focus is on metaphysics & the ethics of human freedom in the early modern period. In this episode, we talk about the historical origin of witches & word choice, the connection between female sexual satisfaction & witches, the 1400's witch hunting manual & how time legitimizes magical practices If you like this episode, you'll also like episode 195: ROUNDING UP SUSPICIOUS WOMEN? THE AMERICAN PLAN  Host:  https://www.meredithforreal.com/  https://www.instagram.com/meredithforreal/ meredith@meredithforreal.comhttps://www.youtube.com/meredithforreal  https://www.facebook.com/meredithforrealthecuriousintrovert  Sponsors: https://www.jordanharbinger.com/starterpacks/ https://www.historicpensacola.org/about-us/  00:00 — Generations of witches in pop culture01:20 — First encounters with “I'm a witch”02:10 — The word wicce and its earliest meaning04:00 — Magic before evil: shifting definitions05:00 — Witch as a living, changing word06:10 — Salem isn't the beginning07:00 — The 1487 bestseller that fueled hunts09:00 — Sex, power, and the devil's contract10:30 — Why ridiculous ideas still matter11:30 — How witch manuals went viral13:00 — From Europe to Salem: ideology travels14:00 — What counted as a witch in 1690s Salem15:00 — Tituba's confession and survival strategy17:00 — Executions, prisons, and spectral evidence19:00 — How do you defend against a ghost?20:00 — LSD bread or land grabs? Debunking theories22:30 — Property disputes and colonial lawsuits24:30 — From persecution to empowerment today25:30 — Why modern women claim “witch”27:00 — Moon cycles, ancestors, and ritual29:00 — Ancient solstice parties and survival31:00 — The risks of claiming witchhood32:00 — Are modern witches linked to the executed?34:00 — Saints, voodoo dolls, and cultural taboos36:00 — Whose magic gets mainstreamed?37:00 — Why old beliefs feel more “legit”38:30 — Tarot cards, tradition, and authority39:30 — Crystals, consumerism, and moon circles40:30 — Salem today: trinkets and tourism41:30 — Can spirituality resist commercialization?42:00 — Beyond WitchTok: finding your roots43:30 — Elders, ancestry, and empowerment through knowledge44:30 — Where history, nature, and identity converge45:00 — Closing thoughts + future book teaseRequest to join my private Facebook Group, MFR Curious Insiders https://www.facebook.com/share/g/1BAt3bpwJC/

Send me a DM here (it doesn't let me respond), OR email me: imagineabetterworld2020@gmail.comToday I'm honored to have back on the show for an incredible joint episode: MK ULTRA, ritual abuse and organized abuse survivors, overcomers, thrivers, and badasses, survivor and anti-child trafficking advocates, public whistleblowers, podcasters, and two of my favorite humans in the entire world: Dr. Juliette Engel and Lynne Scott HaggermanJuliette, born in 1955 to CIA- and NSA-connected parents, endured electroshock, LSD, and "Sex Magick" rituals in facilities tied to Disney and Stanford. Escaping at sixteen, she became a radiologist, founded the MiraMed Institute, and launched the Angel Coalition, rescuing thousands from trafficking while exposing elite cover-ups in her memoir, Sparky: Surviving Sex Magick. Lynne, trafficked from birth to age five, survived medical torture, satanic rituals in university tunnels, trafficking by her own family to neighborhood perpetrators, and horrific child auctions. Guided by faith, she built a career as an HR consultant and marathoner, founding QGRIT to heal survivors through her podcast and wellness advocacy, amplifying truths about organized child abuse and elite networks.Juliette and Lynne's testimonies converge like rivers into a storm-swept sea: both women, as infants thrust into CIA-sponsored child slavery, navigated underground facilities rife with ritual abuse and mind control. Universities - which should serve as safe spaces for all - served as above-ground facades for below-ground atrocities, from electroshock and drug-induced fragmentation to exploitation by pedophilic infiltrators in government and entertainment. Juliette's "Sex Magick" programming parallels Lynne's adrenochrome rituals, both rooted in MK ULTRA's goal of creating programmable mind-controlled slaves through trauma. And in their escapes - Juliette's bold teenage rebellion, Lynne's faith-fueled breakthrough - they reclaimed narratives long scripted by shadowy handlers, turning suppressed screams into public indictments that challenge the 1975 Church Committee revelations and demand deeper accountability.On today's episode, they are going to be discussing a few very important topics that truly need greater societal understanding and a call to action including a discussion around Manchurian Candidates, how these MK ULTRA mind control slaves can be programmed to carry out heinous crimes on the government's behalf including things like political and mass shootings, the trans agenda and it's relationship to MK ULTRA and the horrific news headlines that bombard us daily, and so much more. In a world still grappling with hidden predators, their work whispers a universal rallying cry: Rise. Reclaim. Radiate. For in their unbreakable spirits, we see the dawn of justice - not as distant hope, but as the spark within us all, ready to burn away the dark.RECOMMENDED READING - MK ULTRA DOCS: https://nsarchive.gwu.edu/briefing-book/dnsa-intelligence/2024-12-23/cia-behavior-control-experiments-focus-new-scholarlyCONNECT TO LYNNE: Website: https://qgrit.org/YouTube: @LynneScottHaggerman  Rumble: https://rumble.com/c/TheLynneScottHaggermanShow?e9s=src_v1_saX: https://x.com/haggerman91741CONNECT WITH JULIETTE: Website: https://julietteengel.com/CONNECT WITH EMMA / THE IMAGINATION: YouTube: https://www.youtube.com/@imaginationpodcastofficialRumble: https://rumble.com/c/TheImaginationPodcastEMAIL: imagineabetterworld2020@gmail.com OR standbysurvivors@protonmail.comMy Substack: https://emmakatherine.substack.com/BUY ME A COFFEE: httSupport the show

durée : 00:59:38 - LSD, la série documentaire - par : Tao Favre - Sobriété et électrification sont les mots d'ordre de la transition. Mais, c'est sans compter cette nouvelle infrastructure énergivore qui est en train de se déployer à travers le monde : celle du numérique, de l'IA et des data centers. - réalisation : Gaël Gillon

durée : 00:59:38 - LSD, la série documentaire - par : Tao Favre - Nous assistons à la relance massive du nucléaire en France. Une transition véritable ne consisterait-elle pourtant pas à faire de l'énergie un bien commun, et ce, à une échelle qui donnerait sens au concept de souveraineté ? - réalisation : Gaël Gillon

durée : 00:59:51 - LSD, la série documentaire - par : Tao Favre - L'horizon calciné promis par la société industrielle bas-carbone occulte celui d'une société écologique. Il s'agit désormais d'affirmer ce lieu dans toute sa complexité : le jardin, dont les fruits les plus suaves sont la liberté et l'émancipation. - réalisation : Gaël Gillon

durée : 01:02:05 - LSD, la série documentaire - par : Tao Favre - Remplacer les énergies fossiles par des métaux, voilà le projet de la transition qui précipite le monde dans une ruée minière et annonce le retour des mines en France. Comment une industrie si polluante peut-elle venir au secours de la planète ? - réalisation : Gaël Gillon

Ospiti della 178° puntata di Illuminismo Psichedelico, andata in scena al Samichay 2025, sono state la sociologa Denise De Gouges e la scrittrice Ilaria Giannini, con cui abbiamo parlato del corpo femminile come campo di battaglia e di cura in ambito psichedelico. Ilaria e Denise sono autrici della rubrica Trip Sisters sulla pagina Instagram di Illuminismo Psichedelico, uno spazio in cui propongono citazioni di donne che nel tempo si sono espresse nell'ambito della cultura psichedelica. In questa puntata, che fa parte della serie che stiamo realizzando con Ilaria e Denise sui temi del femminile in ambito psichedelico, le nostre due alfiere del femminismo lisergico ci hanno parlato del modo in cui il genere influenza l'assunzione di sostanze psichedeliche e dell'elaborazione di tali esperienze, sia da un punto di vista fisico che da quello psicologico e sociale. Il tutto come sempre partendo da una vasta base bibliografica esplicitamente citata nel corso della puntata. 

--{ "September Patchwork Quilt"}-- CTTM book club on Telegram, Fiona asks 'How did you discover Alan Watt's work?' - A patchwork quilt of Alan Watt's talks in the month of September; remembering Hamish - Bridging emotion and reason - Making connections about Charlie Kirk and Nick Fuentes with Joe on the latest Real History episode: As Alan always said, 'Your leaders are supplied.' - Seasons change - PM Keir Starmer says a digital ID will be mandatory to work in the UK - Christian Nationalism; the 1930s scenario - Alan Watt on Sweet Liberty, Sept. 28, 2006: This earth plane is where spirit and matter meet; our personal choices matter. Alan Watt on The Grassy Knoll, Sept. 28, 2006: Think tanks - Deviant priesthood - Alan Watt on World Review Commentary, Sept. 2, 2007: RE-written history, a new FICTION for your generation; removal of "discordant" parts of history - Pacification of public - Club of Rome - A global system. - Alan Watt on RBN, Sept. 28, 2007: October in high occult - the New Age, MI5, MI6, Aleister Crowley, OTO - Psychedelic drugs, LSD, resulting in death, schizophrenia, brain damage - Drug promotion is done from the top. - Alan Watt on RBN, Sept. 28, 2009: The new priesthood (Experts) of science and greening - Reality creation, television images; "Most-Trusted" newscasters - New feudal society for New Age - Malthus - Symbiosis of elite masters and masses of slaves - The Dead - Survival instincts, wild vs. domesticated animals - Alan Watt blurb Sept. 18, 2016: Hamish.

Comedian Michelle Murphy (@meeshoffleash) joins Andy, Matt and Jesse to talk about playing tennis for Grinnell, the Enhanced Games, celebrities trying their hands at winter sports, Jesse's accidental mermaid book purchase and the Dr. Seuss book he was aiming for, Burning Man missionaries, LSD to fight anxiety and surprisingly not too uncommon iridescent mammals.

The Deadcast unpacks the two-part extra-heady “King Solomon's Marbles”/'Stronger Than Dirt or Milkin' the Turkey,” using the instrumental to get into the Dead's 1975 dalliances with holography, as well as Phil Lesh's other unfinished pieces from Blues For Allah.Guests: David Lemieux, Ned Lagin, Ron Rakow, Eugene Dolgoff, Michael Parrish, Ed Perlstein, Keith Eaton, Nicholas G. Meriwether, Shaugn O'Donnell, Chadwick JenkinsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With nearly one in ten newborns in the US requiring care in a Neonatal Intensive Care Unit, the importance of NICUs has never been more clear. On today's episode of Raise the Line, we're shining a light on the extraordinary world of NICUs with Lindsay Howard, a veteran nurse with over 17 years of experience caring for premature and critically ill infants. She currently works in a Level IV NICU at Children's Memorial Hermann Hospital in Houston, one of the most advanced neonatal units in the country. “We call ourselves ‘the ER of the neonate world' because we're never full. We have to make space no matter what comes in off the street, and at the biggest medical center in the world, we see all the things,” she explains. In this enlightening conversation with host Lindsey Smith, Howard describes how advances in medicine have made it possible to provide more types of care for younger and smaller babies, creating a need for NICU nurses to develop subspecialties. In her case, Howard is on a dedicated team that handles the placement and maintenance of all central line IVs, and has earned certifications in neonatal and pediatric chemotherapy and biotherapies. “We see babies that we may not have seen before being born with cancerous tumors who need chemotherapy to try and eliminate it, or just give them more time with their family.” This is a revealing look inside the workings of a top tier NICU where you'll learn about approaches to care that support healthy neurodevelopment, how clinical staff handle the emotional challenges of the job, and how her own experience as a mother with twins needing NICU care impacted her work.  Mentioned in this episode:Children's Memorial Hermann Hospital If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

"An Idiom is a group of words that suggest a meaning different than their specific words. Many of them come from the world of music and we have created a solid list. You will recognize a lot of them."

Julia is joined by genius mind P.E. Moskowitz for a conversation about their new memoir Breaking Awake, which chronicles the mental breakdown that drove them to experiment with drugs, reckon with trauma, and draw meaning from suffering. From Klonopin and SSRIs to ketamine and LSD, they consider what our reliance on substances reveals about our modern world. Are drugs soothing us, transforming us, or just reflecting our pain? Digressions include P.E.'s commandment to “go out and get weird with it,” the dark headspace where internet mantras start to feel profound, and the unfortunate but honest truth that the only way out is through. This episode was produced by Julia Hava and edited by Livi Burdette.  Check out P.E.'s book Breaking Awake: A Reporter's Search for a New Life, and a New World, Through Drugs and their Substack Mental Hellth. To support the podcast on Patreon and access 50+ bonus episodes, mediasodes, and more, visit patreon.com/binchtopia and become a patron today.  

Key Points Robin Swan explains her indigenous background and lifelong experience with psychotropic substances through the Native American church, having used peyote since childhood and incorporating psilocybin into her apothecary practice since 2014.Psilocybin mushrooms grow on every continent making them an open practice for humanity, with mycelium mapping similarly to the human central nervous system and representing the first life form to emerge from water according to creation theory.Depression and brain cancers became the primary focus for incorporating psilocybin into Swan's practice because cannabis wasn't adequately addressing these conditions, particularly given that mushrooms create neuroplasticity and open new neural pathways.Working with NFL players and pro sports athletes for 15 years revealed that psilocybin significantly helped traumatic brain injury and concussion recovery where cannabis had limited effectiveness.One unnamed NFL commentator client with 12 concussions showed dramatic improvement within three weeks of psilocybin microdosing, regaining speech clarity, eliminating blank stares, and completely stopping massive migraines that pharmaceuticals couldn't treat.Different psilocybin mushroom varieties serve distinct therapeutic purposes, with cubensis being electric and external for traditional psychedelic experiences, while azurescens provide internal experiences that create neuroplasticity specifically beneficial for brain cancer patients.Clinical studies from Johns Hopkins University, Harvard, and Emory University have documented psilocybin's therapeutic potential across 170 studies covering treatment-resistant depression, anxiety, PTSD, Alzheimer's, Parkinson's, chronic pain, and immune system modulation.Parkinson's disease treatment with psilocybin shows remarkable results in reducing shakiness and mood swings while helping patients navigate daily challenges, while Alzheimer's patients become more fluid and maintain better memory connections.Psilocin, the active ingredient in psilocybin, remains active for only three days once extracted and requires specific ingestion methods, with lemon juice extraction providing faster onset within 15 minutes compared to capsules taking up to four hours.Swan Apothecary offers various psilocybin products including capsules, chocolate bars, lemon-extracted psilocin products, and a "hero dose" journey product containing 3.5 grams, all requiring two years of research and development before market release.Cannabis and psilocybin produce completely different experiences, with cannabis providing cannabinoid profiles while mushrooms maintain individual properties and create visions, heart-opening effects, and consciousness expansion that may have driven human evolution from apes.Common misconceptions about psilocybin include fears of wall-melting hallucinations and bad experiences, though the substance is safer than LSD as a natural fungus lasting 4-6 hours with potential weeks-long afterglow effects.Proper dosing and timing matter significantly for psilocybin effectiveness, with insufficient doses or full stomachs preventing activation, while the substance helps end-of-life patients live longer and have meaningful conversations with loved ones.Swan emphasizes that mushrooms help people embrace living in the present moment rather than fighting for future life, citing client Sally who lived nine years beyond her initial diagnosis and taught the importance of conscious, empowered living during terminal illness. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textIn today's episode of the Psychedelic Therapy Frontiers podcast we discuss a paper recently published in JAMA (Journal of the American Medical Association) entitled, “Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial.” This is a report on the results from Mind Medicine's phase 2b clinical trial that Reid and I both had the pleasure of working on at Numinus Network's clinical trial site, Cedar Clinical Research. We discuss what GAD is, a brief history of LSD, why LSD might be helpful for anxiety, the study design, the difference between session monitoring vs psychedelic-assisted therapy, and more. Near the end of the episode we briefly discuss another recently published paper, this one on psilocybin and how the phenomenology of a psychedelic experience might contribute to positive psychological changes. For those of you who are new to the show, welcome! Psychedelic Therapy Frontiers is brought to you by Numinus Network and is hosted by Dr. Steve Thayer and Dr. Reid Robison.https://jamanetwork.com/journals/jama/article-abstract/2838505https://link.springer.com/article/10.1007/s43440-025-00742-5Learn more about our podcast at https://numinusnetwork.com/learn/podcast/Learn more about psychedelic therapy training opportunities at https://numinusnetwork.com/training/Learn more about our clinical trials at https://www.numinusnetwork.com/researchLearn more about Numinus at https://numinusnetwork.com/Email us at ptfpodcast@numinus.com Follow us on Instagram: https://www.instagram.com/drstevethayer/https://www.instagram.com/innerspacedoctor/https://www.instagram.com/numinushealth/

Journalist Kasper Lundberg har sat sin egen krop på spil i jagten på svar: Kan psykedeliske stoffer som LSD, MDMA og psilocybinsvampe virkelig åbne døren til heling og forandring, eller er det et i bedste fald et farligt eksperiment? Samtidig vokser den videnskabelige interesse, og i Danmark er politikerne begyndt at tale om at slippe de forbudte stoffer ind i psykiatrien. I dag spørger vi: Er vi på vej mod et psykedelisk gennembrud eller gentager vi fortidens fejltagelser? Vært: Simon Stefanski. Program publiceret i DR Lyd d. 19. september 2025.

The agencies tasked with defending America have a shocking secret history of attacking its own people. DARPA developed Agent Orange that poisoned countless veterans, while the CIA conducted brutal mind control experiments through MK-Ultra, dosing unsuspecting citizens with LSD and worse.  From Operation Gladio's false flag terrorism to domestic surveillance programs targeting activists and journalists, declassified documents reveal decades of government crimes hidden behind national security claims.  These operations cost thousands of American lives, yet almost no one faced consequences. The real conspiracy isn't what they're hiding - it's what they've already admitted to doing. https://www.youtube.com/watch?v=1BKowVsgjPM&t=1457s

durée : 00:59:06 - LSD, la série documentaire - par : Hajer Ben Boubaker - L'héroïne s'est ancrée durablement en France, en partie à cause des défaillances du système de santé. Face à l'épidémie, les cités s'organisent seules. Pendant ce temps, les acteurs associatifs plaident pour une politique de réduction des risques. - réalisation : Gilles Blanchard

durée : 00:58:41 - LSD, la série documentaire - par : Hajer Ben Boubaker - Dans les années 1980, héroïne et sida frappent durement les quartiers populaires, emportant une génération, notamment de jeunes d'origine maghrébine. Sans données officielles, ce drame reste invisibilisé, révélant l'abandon des banlieues - réalisation : Gilles Blanchard

durée : 00:59:43 - LSD, la série documentaire - par : Hajer Ben Boubaker - A la fin des années 60, l'héroïne, d'abord marginale, séduit une jeunesse post-68 en quête de sensations fortes. Face à la diffusion nouvelle des drogues, la France adopte d'emblée une politique répressive. - réalisation : Gilles Blanchard

durée : 00:59:05 - LSD, la série documentaire - par : Hajer Ben Boubaker - À la fin des années 70, l'héroïne touche tous les milieux sociaux. En banlieue, une jeunesse issue de l'immigration maghrébine découvre cette drogue sur fond de racisme, de désindustrialisation et de profonds bouleversements sociaux. - réalisation : Gilles Blanchard

Join us LIVE tonight at 7pm EST as we dive into the odd coincidences of Kerry Thornley and Lee Harvey Oswald. Was Thornley brilliant...crazy...or a little bit of both? Or is it the Dischordian Goddess Eris playing tricks on us? And why Switzerland? The answer might suprise you!Oswald book - https://a.co/d/dWrkYnCIdle Warriors book - https://a.co/d/hZwatzsSilk City Hot Sauce - https://silkcityhotsauce.com Use our code GUNMAN at checkout to save 20% off entire order!Music By - Lee Harold OswaldA Loose Moose ProductionBBB&JOEBBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-lone-gunman-podcast-jfk-assassination--1181353/support.

Norman Ohler is a historian and author of "Blitzed: Drugs in the Third Reich," a book that investigates the role of psychoactive drugs, particularly stimulants such as methamphetamine, in the military history of World War II. It is a book that two legendary historians Ian Kershaw and Antony Beevor give very high praise for its depth of research. Norman also wrote "Tripped: Nazi Germany, the CIA, and the Dawn of the Psychedelic Age", and he is working on a new book "Stoned Sapiens" looking at the history of human civilization through the lens of drugs. Thank you for listening ❤ Check out our sponsors: https://lexfridman.com/sponsors/ep481-sc See below for timestamps, transcript, and to give feedback, submit questions, contact Lex, etc. Transcript: https://lexfridman.com/norman-ohler-transcript CONTACT LEX: Feedback - give feedback to Lex: https://lexfridman.com/survey AMA - submit questions, videos or call-in: https://lexfridman.com/ama Hiring - join our team: https://lexfridman.com/hiring Other - other ways to get in touch: https://lexfridman.com/contact EPISODE LINKS: Stoned Sapiens Substack: https://substack.com/@stonedsapiens Norman's X: https://x.com/normanohler Norman's Instagram: https://www.instagram.com/normanohler Norman's YouTube: https://www.youtube.com/@Norman-Ohler Norman's Website: https://www.normanohler.de Norman's books: https://amzn.to/46uNS18 Blitzed: https://amzn.to/4mmY2XC The Bohemians: https://amzn.to/3KubPhK Tripped: https://amzn.to/4nEy7eX SPONSORS: To support this podcast, check out our sponsors & get discounts: UPLIFT Desk: Standing desks and office ergonomics. Go to https://upliftdesk.com/lex Fin: AI agent for customer service. Go to https://fin.ai/lex Shopify: Sell stuff online. Go to https://shopify.com/lex LMNT: Zero-sugar electrolyte drink mix. Go to https://drinkLMNT.com/lex Hampton: Community for high-growth founders and CEOs. Go to https://joinhampton.com/lex OUTLINE: (00:00) - Introduction (01:09) - Sponsors, Comments, and Reflections (09:00) - Drugs in post-WWI Germany (19:18) - Nazi rise to power (23:45) - Hitler's drug use (29:37) - Response to historian criticism (46:16) - Pervitin (1:00:15) - Blitzkrieg and meth (1:18:52) - Erwin Rommel (Crystal Fox) (1:23:02) - Dunkirk (1:31:06) - Hitler's drug addiction (1:47:03) - Methamphetamine (1:48:57) - Invasion of Soviet Union (2:07:54) - Cocaine (2:16:49) - Hitler's last days (2:36:48) - German resistance against Nazis (2:58:59) - Totalitarianism (3:04:09) - Stoned Sapiens - Drugs in human history (3:19:20) - Religion (3:30:09) - LSD, CIA, and MKUltra (3:55:39) - Writing on drugs (4:08:40) - Berlin night clubs (4:19:14) - Greatest book ever written

On this episode of Wife of Crime I tell Russ about the CIA's secret mind-control program known as MK Ultra. In the 1960s, a CIA scientist named Frank Olson fell from a 10th-floor Manhattan hotel window. His family was told it was suicide. But that “official story” would turn out to be the first crack exposing a web of corruption, cover-ups, and shocking experiments performed on unsuspecting citizens. This case isn't just about one man's mysterious death, it's a reminder of how easily truth can be buried when powerful institutions control the narrative. Moral of this story... In the ‘60s it was LSD. Today it's algorithms. Either way, someone is always trying to influence how you think. Big Shout out to Myrtle for helping me research this heavy hitter! Learn more about your ad choices. Visit megaphone.fm/adchoices

Send me a DM here (it doesn't let me respond), OR email me: imagineabetterworld2020@gmail.comToday I'm honored to have back on the show once again: MK ULTRA, satanic ritual abuse, and organized abuse survivor, overcomer and thriver, loving mother, published writer and author, content creator and podcaster, Physician and Radiologist turned activist, Founder of the Angel Coalition and Co-Founder of Women and Children First and the Babushka Brigade, Star Fort enthusiast, award winner of the University of Washington School of Medicine's prestigious Humanitarian Award, podcast regular, and one of my dearest friends: Dr. Juliette EngelBorn in 1949 into a US Intelligence family, Juliette was sold at age six into the CIA's MK ULTRA program, a sinister operation of trauma-based mind control authorized in 1953. Within MONARCH - as Juliette describes as ‘MK ULTRA for children', she endured unimaginable horrors as a small child - LSD, hypnosis, ritualistic and organized abuse, sex magick, trafficking across borders… and this only scratches the surface. Her childhood was stolen to no avail and her mind fragmented by trauma-induced dissociation. Yet, at 16, Juliette escaped, piecing together a new life with no memory of her past.Amnesia became her shield as she pursued a medical degree, specializing in radiology and building a thriving ultrasound practice in Bellevue, Washington. Counseling in the 1990s helped unlock her suppressed memories, and despite threats from her parents, she faced her truth head-on. In 1992, she sold her practice and founded the MiraMed Institute in post-Soviet Russia. By 1999, in Moscow, she launched the Angel Coalition - an underground railroad rescuing thousands of trafficking victims. Her work exposed the global child sex trade, earning her the University of Washington School of Medicine's Humanitarian Award. Her 2021 memoir, Sparky: Surviving Sex Magick, is a gripping MK ULTRA exposé, using her own testimony to shine a light on the darkness she survived as a child. Through podcasts and advocacy, she connects her past to modern trafficking networks, warning of MK ULTRA's lingering influence. Today, Juliette is back again to talk about some current events helping and shaping the survivor community along with a discussion on how survivors can take their power back and move beyond the devastation of victim-hood. A mother, podcaster, and faith-driven warrior, Juliette transforms pain into purpose, inspiring a movement against exploitation. Her journey - from the depths of darkness to a radiant beacon of hope - ignites a fire in us all, proving that one unyielding soul can shatter chains, heal hearts, and inspire a world to rise against injustice with unstoppable courage.RECOMMENDED READING - MK ULTRA DOCS: https://nsarchive.gwu.edu/briefing-book/dnsa-intelligence/2024-12-23/cia-behavior-control-experiments-focus-new-scholarlyCONNECT WITH JULIETTE: Website: https://julietteengel.com/CONNECT WITH EMMA / THE IMAGINATION: YouTube: https://www.youtube.com/@imaginationpodcastofficialRumble: https://rumble.com/c/TheImaginationPodcastEMAIL: imagineabetterworld2020@gmail.com OR standbysurvivors@protonmail.comMy Substack: https://emmakatherine.substack.com/BUY ME A COFFEE: https://www.buymeacoffee.com/theimaginationAll linkSupport the show

durée : 00:53:24 - LSD, la série documentaire - par : Kristel Le Pollotec - Pour un romancier, écrire un best-seller peut être une catastrophe. Comment s'accommoder, après avoir vendu plus de 500 000 livres, à des tirages de plus en plus maigres… À l'inverse, et peut-être pire encore, comment survivre à l'étiquette infamante d'auteur à succès. - réalisation : Nathalie Battus

“When you think about where we were as a country before Medicare and Medicaid were created and where we are now, it's an incredible story,” says Chiquita Brooks-LaSure, who until earlier this year was the administrator for the Centers for Medicare and Medicaid Services (CMS). In a recent essay for The Century Foundation, where she is now a senior fellow, Brooks-LaSure used the 60th anniversary of enactment of those foundational insurance programs to help put their impact on individual Americans, the healthcare system and society at large in perspective. One prominent example is the desegregation of hospitals, which was achieved in part by withholding reimbursements for care unless facilities served Blacks as well as whites. Another is making it possible for more people with disabilities to live at home instead of in institutional settings. But as you'll hear in this probing Raise the Line conversation with host Lindsey Smith, Brooks-LaSure worries that many gains in coverage and other progress made over the years through Medicare, Medicaid and the Child Health Insurance Program (CHIP) are at risk because of a new federal law that calls for a trillion dollar decrease in spending, resulting in potentially millions of people losing their coverage, cuts to clinical staff and medical services, and the closure of hospitals and clinics, especially in rural areas. “Most rural hospitals in this country are incredibly dependent on both Medicare and Medicaid to keep their doors open and there's an estimate that over 300 hospitals will close as a result of this legislation, so that, I think, is a place of incredible nervousness.” Whether you are a patient, provider, policymaker or health system leader, this is a great opportunity to learn from an expert source about the range of potential impacts that will flow from changes to critically important insurance programs that provide coverage to 40% of adults and nearly 50% of children in the U.S. Mentioned in this episode:The Century FoundationEssay on 60th Anniversary of Medicare & Medicaid If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

"This past 4th of July someone posted the Preamble and I wondered who the singer was. I watched a few more and wondered who they were. We will answer that today. We will play some of their Schoolhouse Rock song and then one of their singles. Plus we have some trivia about the show."